SIGA (SIGA) 10-K 7 Mar 17 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information Document - USD ($)	12 Months Ended
	Dec. 31, 2016	Feb. 28, 2017	Jun. 30, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	SIGA TECHNOLOGIES INC
Entity Central Index Key	1,010,086
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Trading Symbol	SIGA
Document Type	10-K
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding		78,780,059
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 54,284,296

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2016	Dec. 31, 2015
ASSETS
Cash and cash equivalents	$ 28,701,824	$ 112,711,028
Restricted cash and cash equivalents-short term	10,138,890	0
Accounts receivable	3,154,370	3,676,730
Inventory	26,209,964	12,447,088
Prepaid expenses and other current assets	954,426	623,983
Total current assets	69,159,474	129,458,829
Property, plant and equipment, net	299,477	449,825
Restricted cash and cash equivalents-long term	17,333,332	0
Deferred costs	72,649,277	52,936,428
Goodwill	898,334	898,334
Other assets	642,083	1,989,520
Total assets	160,981,977	185,732,936
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Accounts payable	2,517,072	3,944,476
Accrued expenses and other current liabilities	4,584,752	3,388,608
Warrant liability	6,727,409	0
Total current liabilities	13,829,233	7,333,084
Deferred revenue	367,483,905	255,258,371
Deferred income tax liability, net	286,066	265,643
Other liabilities	247,989	332,218
Liabilities subject to compromise	0	206,972,170
Loan payable	66,553,053	0
Total liabilities	448,400,246	470,161,486
Stockholders’ deficit
Common stock ($.0001 par value, 600,000,000 shares authorized, 78,692,612 and 54,114,296 issued and outstanding at December 31, 2016, and December 31, 2015, respectively)	7,869	5,411
Additional paid-in capital	213,714,154	177,008,371
Accumulated deficit	(501,140,292)	(461,442,332)
Total stockholders’ deficit	(287,418,269)	(284,428,550)
Total liabilities and stockholders’ deficit	$ 160,981,977	$ 185,732,936

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares	Dec. 31, 2016	Dec. 31, 2015
Balance Sheet Parenthetical [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	600,000,000	600,000,000
Common stock, shares issued	78,692,612	54,114,296
Common stock, shares outstanding	78,692,612	54,114,296

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Revenues
Research and development	$ 14,987,628	$ 8,175,878	$ 3,139,835
Operating expenses
Selling, general and administrative	13,713,635	10,582,068	12,646,653
Research and development	19,710,673	13,130,529	10,707,354
Patent preparation fees	909,376	1,009,053	987,777
Litigation accrual expense	0	14,407,494	188,465,065
Interest on PharmAthene liability	11,668,900	0	0
Total operating expenses	46,002,584	39,129,144	212,806,849
Operating loss	(31,014,956)	(30,953,266)	(209,667,014)
Decrease (increase) in fair value warrant liability	894,785	0	(313,425)
Interest expense	(2,395,517)	(266,726)	(455,810)
Backstop fee - see Note 8	(1,764,240)	0	0
Other income, net	102,324	42,202	1,065
Reorganization items, net	(3,716,902)	(7,811,551)	(2,126,536)
Loss before income taxes	(39,684,076)	(38,989,341)	(211,934,870)
Provision for income taxes	(13,884)	(461,983)	(53,528,268)
Net and comprehensive loss	$ (39,697,960)	$ (39,451,324)	$ (265,463,138)
Earnings (loss) per share: basic and diluted (usd per share)	$ (0.69)	$ (0.73)	$ (4.97)
Weighted average shares outstanding: basic and diluted (in shares)	57,188,503	53,777,687	53,419,686

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT - USD ($)	Total	Common Stock	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)
Total stockholders' equity (in shares) at Dec. 31, 2013		53,108,844
Total stockholders' equity at Dec. 31, 2013	$ 16,975,468	$ 5,310	$ 173,498,028	$ (156,527,870)	$ 0
Increase (Decrease) in Stockholders' Equity
Net income (loss)	(265,463,138)			(265,463,138)
Issuance of common stock upon exercise of stock options and warrants (in shares)		521,327
Issuance of common stock upon exercise of stock options and warrants	102,035	$ 54	101,981
Stock-based compensation	2,299,098		2,299,098
Change in excess tax benefit stock-based compensation, value	0
Payment of common stock tendered for employee stock-based compensation tax obligations (in shares)		(125,875)
Payment of common stock tendered for employee stock-based compensation tax obligations	(415,940)	$ (13)	(415,927)
Total stockholders' equity (in shares) at Dec. 31, 2014		53,504,296
Total stockholders' equity at Dec. 31, 2014	(246,502,477)	$ 5,351	175,483,180	(421,991,008)	0
Increase (Decrease) in Stockholders' Equity
Net income (loss)	(39,451,324)			(39,451,324)
Issuance of common stock upon exercise of stock options and warrants (in shares)		610,000
Issuance of common stock upon exercise of stock options and warrants	12,200	$ 60	12,140
Stock-based compensation	1,528,582		1,528,582
Change in excess tax benefit stock-based compensation, value	(15,531)		(15,531)
Payment of common stock tendered for employee stock-based compensation tax obligations	$ 0
Total stockholders' equity (in shares) at Dec. 31, 2015	54,114,296	54,114,296
Total stockholders' equity at Dec. 31, 2015	$ (284,428,550)	$ 5,411	177,008,371	(461,442,332)	0
Increase (Decrease) in Stockholders' Equity
Net income (loss)	(39,697,960)			(39,697,960)
Issuance of common stock upon exercise of RSU's, shares		483,335
Issuance of common stock upon exercise of RSU's, value		$ 48	(48)
Stock-based compensation	775,541		775,541
Change in excess tax benefit stock-based compensation, value	0
Payment of common stock tendered for employee stock-based compensation tax obligations (in shares)		(136,744)
Payment of common stock tendered for employee stock-based compensation tax obligations	(428,009)	$ (13)	(427,996)
Issuance of common stock associated with rights offering, shares		23,523,195
Issuance of common stock associated with rights offering, value	34,596,469	$ 2,352	34,594,117
Issuance of common stock associated with backstop agreement, shares		708,530
Issuance of common stock associated with backstop agreement, value	$ 1,764,240	$ 71	1,764,169
Total stockholders' equity (in shares) at Dec. 31, 2016	78,692,612	78,692,612
Total stockholders' equity at Dec. 31, 2016	$ (287,418,269)	$ 7,869	$ 213,714,154	$ (501,140,292)	$ 0

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities:
Net loss	$ (39,697,960)	$ (39,451,324)	$ (265,463,138)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and other amortization	174,275	247,357	351,561
Increase in fair value of warrant liability	894,785	0	(313,425)
Stock-based compensation	775,541	1,574,038	2,435,462
Gain on sale of assets	0	0	(345,658)
Non-cash backstop fee	(1,764,240)	0	0
Loss on disposal of assets	0	243,707	0
Non-cash interest expense	566,779	10,052	31,175
Interest expense on term loan - paid with restricted cash	1,222,222	0	0
Changes in assets and liabilities:
Accounts receivable	522,360	(3,185,098)	490,391
Inventory	(13,762,876)	6,597,389	1,470,872
Deferred costs	(19,712,849)	(20,075,554)	(10,277,672)
Prepaid expenses and other current assets	(330,443)	229,266	(236,134)
Other assets	80,928	0	43,186
Deferred income taxes, net	20,423	21,103	53,569,071
Accounts payable, accrued expenses and other current liabilities	(177,342)	1,862,779	(4,436,468)
Liabilities subject to compromise	(160,072,170)	(192,067,797)	399,039,967
Deferred revenue	112,225,534	255,176,572	(162,140,390)
Other liabilities	(84,228)	(73,107)	(42,280)
Net cash (used in) provided by operating activities	(115,590,781)	11,109,383	14,176,520
Cash flows from investing activities:
Capital expenditures	(23,927)	(108,953)	(28,046)
Proceeds from sale of assets	0	0	569,607
Return of collateral for surety bond	1,212,591	0	0
Restricted cash	0	4,000,000	(4,000,000)
Net cash provided by (used in) investing activities	1,188,664	3,891,047	(3,458,439)
Cash flows from financing activities:
Net proceeds from exercise of warrants and options	0	12,200	102,035
Net proceeds from equity rights offering - net of offering costs	34,596,468	0	0
Payment of employee tax obligations for common stock tendered	(428,009)	0	(415,940)
Debt issuance costs	(3,775,546)	0	0
Repayment of long-term debt	0	(2,000,000)	(2,000,001)
Excess tax benefit from stock-based compensation	0	(15,531)	0
Net cash provided by (used in) financing activities	30,392,913	(2,003,331)	(2,313,906)
Net (decrease) increase in cash and cash equivalents	(84,009,204)	12,997,099	8,404,175
Cash and cash equivalents at beginning of period	112,711,028	99,713,929	91,309,754
Cash and cash equivalents at end of period	28,701,824	112,711,028	99,713,929
Supplemental disclosures of cash flows information:
Portion of Term Loan paid directly to PharmAthene by the Lender in satisfaction of the PharmAthene claim; such liability is part of the Liabilities Subject to Compromise line item	46,900,000	0	0
Cash interest paid on PharmAthene liability	11,668,900	0	0
Cash interest paid on Term Loan from restricted cash	1,222,222	0	0
Cash income taxes paid (refund)	500,975	(420,029)	728,442
Reclass of common stock warrant liability to additional paid-in capital upon warrant exercise	0	0	751,370
Fair value of warrant, at issuance date, in connection with loan agreement and recorded as warrant liability	$ 5,832,624	$ 0	$ 0

Organization and Basis of Prese

Organization and Basis of Presentation	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure	Organization and Basis of Presentation Description of Business SIGA Technologies, Inc. (“SIGA” or the “Company”) is a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats. The Company's lead product is TPOXX®, an orally administered antiviral drug that targets orthopoxvirus infections, including smallpox. While TPOXX® is not yet approved as safe or effective by the U.S. Food & Drug Administration, it is a novel small-molecule drug that is being delivered to the Strategic National Stockpile under Project Bioshield. Chapter 11 Filing On September 16, 2014 (the “Petition Date”), the Company filed a voluntary petition for relief under chapter 11 of Title 11 of the United States Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the Southern District of New York (the “Bankruptcy Court”) chapter 11 Case Number 14-12623 (SHL). The Company operated its business as a “debtor-in-possession” until its emergence from chapter 11 of the Bankruptcy Code. The Company emerged from chapter 11 of the Bankruptcy Code on April 12, 2016. The Company did not apply the provision of fresh start accounting as ownership of existing shares of the Company's common stock remained unaltered by the Third Amended Chapter 11 Plan as discussed below in the "Plan of Reorganization". The chapter 11 case preserved the Company's ability to satisfy its commitments under the BARDA Contract (as defined in Note 3 to the financial statements) and preserved its operations, which likely would have been jeopardized by the enforcement of a judgment stemming from the litigation with PharmAthene, Inc. (“PharmAthene”) (see “PharmAthene Litigation” below). While operating as a debtor-in-possession under chapter 11, the Company pursued an appeal of the Delaware Court of Chancery Final Order and Judgment, without having to post a bond. Plan of Reorganization On April 7, 2016, the Company filed its Third Amended Chapter 11 Plan (the "Plan"). The Plan addressed, among other things, how the Company would treat and satisfy its liabilities relating to the period prior to the commencement of its chapter 11 case, including all claims held by PharmAthene. On April 8, 2016, the Bankruptcy Court confirmed the Plan and on April 12, 2016, the Plan became effective (the "Effective Date of the Plan"). The Plan provided for, among other things: • The immediate payment in cash in full of prepetition unsecured claims (other than PharmAthene’s claim). The Company has paid approximately $800,000 to satisfy the claims. • The Company could have treated PharmAthene’s claim under the Plan by one of three options: (i) payment in full in cash of the Company’s obligation under the Delaware Court of Chancery Final Order and Judgment by a certain date (ii) delivery to PharmAthene of 100% of newly-issued stock of the Company, with all existing shares of the Company’s common stock would have been cancelled with no distribution to existing stockholders on account thereof; or (iii) such other treatment as would have mutually agreed upon by the Company and PharmAthene. • On the Effective Date of the Plan, the Company paid $5 million to PharmAthene, which amount was applied against PharmAthene's claim. On July 8, 2016, pursuant to the Plan, the Company delivered to PharmAthene a notification (the “Notification”) of its intention to satisfy PharmAthene's claim by payment in full in cash, and at that time paid PharmAthene $20 million , which was applied against its claim. As a consequence of the Notification and the payment of $20 million to PharmAthene, the Company had until October 19, 2016 (“Final Treatment Date”) to settle the PharmAthene claim under the Plan. On August 18, 2016, the Bankruptcy Court entered an order affirming a joint motion to further extend the Final Treatment Date to November 30, 2016, provided that the Company made a $100 million payment to PharmAthene by October 19, 2016 which would be applied against its claim. Between August and early October, the Company paid PharmAthene $100 million in order to satisfy the extension requirement. On November 16, 2016, the Company paid its remaining obligations to PharmAthene under the Plan. In total, a cumulative amount of $217 million (including interest payments at periodic intervals) was paid by the Company to fully satisfy the PharmAthene claim. The chapter 11 case was closed by the Bankruptcy Court on December 22, 2016. PharmAthene Litigation On November 16, 2016, the Company satisfied the Outstanding Judgment (defined in Note 13 to the financial statements) owed to PharmAthene, Inc. in connection with litigation. In total, PharmAthene was paid $217 million in connection with the Outstanding Judgment. See Note 13 to the financial statements for details related to the litigation. Liquidity The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern and contemplate the realization of assets and the satisfaction of liabilities in the normal course of business. With the receipt of the $8.5 million product delivery payment in February 2017, the Company is not entitled to receive any additional procurement-related payments under the current BARDA Contract (Note 3) until FDA approval of TPOXX® has been achieved and until a cumulative 2 million courses of TPOXX® have been delivered to the Strategic Stockpile. Upon meeting these requirements, the Company is entitled to a $41 million hold back payment under the BARDA contract. Based on a targeted NDA filing for TPOXX® by the end of 2017, it is currently anticipated that the Company will be eligible to receive the $41 million hold back payment in the second half of 2018. In the event that the Company does not receive a substantial portion of the hold back payment by the third quarter of 2018, then, based on current operating costs, the Company will require additional sources of funding to continue operations and prevent an event of default under the Term Loan (Note 7). In this case, the Company would seek to increase cash liquidity by: raising proceeds through a financing, a new contract for TPOXX® or any other product, a sale of assets, or the modification of the existing BARDA Contract; by significantly reducing its operating expenses; or by modifying the terms of the Loan Agreement. There can be no assurance that the Company will cumulatively deliver 2 million courses of TPOXX® to the Strategic Stockpile, or that TPOXX® will receive FDA approval on a timely basis, if at all. Furthermore, there can be no assurance that the Company would be able to raise proceeds, if needed, through a financing, a new contract for TPOXX® or any other product, a sale of assets or the modification of the existing BARDA Contract, significantly reduce its operating expenses, or that the lenders would agree to modify the Term Loan Agreement, if needed. Loan Agreement On September 2, 2016, the Company entered into a loan and security agreement (as amended from time to time, the “Loan Agreement”) with OCM Strategic Credit SIGTEC Holdings, LLC (“Lender”), pursuant to which the Company received $80 million on November 16, 2016 having satisfied certain pre-conditions. Proceeds related to the Loan Agreement ( $80 million ) had been placed in an escrow account on September 30, 2016 (the “Escrow Funding Date”). Prior to the Escrow Release Date (November 16, 2016), the Company did not have access to, or any ownership interest in, the escrow account. Until the Escrow Release Date occurred, the Company did not have an obligation to make any payments under the Loan Agreement, no security was granted under the Loan Agreement and no affirmative or negative covenants or events of default were effective under the Loan Agreement. Amounts were held in the escrow account until the satisfaction of certain conditions including the closing of the Rights Offering on November 16, 2016. Amounts held in the escrow account between September 30, 2016 and November 15, 2016 bore interest at a per annum rate equal to the Adjusted LIBOR Rate (as defined in the Loan Agreement) plus 11.50% . Interest on amounts held in the escrow account became payable only when the Escrow Release Date occurred. As part of satisfaction of the PharmAthene claim, funds were released from the escrow account (the date on which such transfer occurred, the “Escrow Release Date”). The Loan Agreement provides for a first-priority senior secured term loan facility in the aggregate principal amount of $80,000,000 (the “Term Loan”), of which (i) $25,000,000 was placed in a reserve account (the “Reserve Account”) only be utilized to pay interest on the Term Loan as it becomes due; (ii) an additional $5,000,000 was also placed in the Reserve Account and up to the full amount of such $5,000,000 may be withdrawn after June 30, 2018 upon the satisfaction of certain conditions, provided that any of such amount is required to fund any interest to the extent any interest in excess of the aforementioned $25,000,000 is due and owing and any of such $5,000,000 remains in the Reserve Account; and (iii) $50,000,000 (net of fees and expenses then due and owing to the Lender) was paid to PharmAthene as part of the final satisfaction of the PharmAthene claim. Interest on the Term Loan is at a per annum rate equal to the Adjusted LIBOR rate plus 11.50% , subject to adjustments as set forth in the Loan Agreement. See Note 7 to the financial statements for additional information. Warrant On September 2, 2016, in connection with the entry into the Loan Agreement, the Company issued a warrant (the “Warrant”) to the Lender to purchase a number of shares of the Company’s common stock equal to $4 million divided by the lower of (i) $2.29 per share and (ii) the subscription price paid in connection with the Rights Offering. The Warrant provided for weighted average anti-dilution protection and is exercisable in whole or in part for ten ( 10 ) years from the date of issuance. The subscription price paid in connection with the Rights Offering was $1.50 ; accordingly, the exercise price of the Warrant has been set at $1.50 per shares and 2.7 million shares can be purchased under the Warrant. The Warrant had a fair value of $6.7 million at December 31, 2016 and is classified as a liability. Rights Offering On November 16, 2016, the Company completed a rights offering (the “Rights Offering”), pursuant to which it raised approximately $35.3 million in gross proceeds through the sale of 23,523,195 shares of its common stock. The Rights Offering was made pursuant to a registration statement on Form S-1 filed with the Securities and Exchange Commission (the “SEC”) and declared effective by the SEC on October 21, 2016. As part of the Rights Offering, each stockholder of the Company received one subscription right for each share of common stock owned as of the record date of October 12, 2016. Each subscription right entitled its holder to invest $0.65 towards the purchase of shares of the Company's common stock at a subscription price equal to the lower of $1.50 or 85% of the volume weighted average price of Company shares during market hours on the expiration date of the Rights Offering. The Rights Offering expired at 5:00 pm, New York City time, on November 8, 2016. Through basic subscriptions and oversubscriptions, the Rights Offering was fully subscribed. The subscription price was set at $1.50 . The Company used the net proceeds of the Rights Offering, together with proceeds from the Loan Agreement (discussed above) and cash on hand, to fully satisfy PharmAthene's claim under the Plan. Rights Offering - Backstop Agreement On October 13, 2016, in connection with the Rights Offering as discussed above, the Company entered into an investment agreement or "Backstop Agreement," with M&F, and other backstop parties (the "Backstop Parties"). Under the term of the Backstop Agreement, the Backstop Parties agreed to purchase, pursuant to a separate private placement, a number of shares of common stock equal to the numbers of shares that would have not been subscribed for in the Rights Offering. Under the Backstop Agreement, the subscription price was set to be equal to the subscription price applicable to all shareholders under the Rights Offering. The Rights Offering was fully subscribed, the Backstop Parties were not required to draw on such commitment. The Company issued 708,530 shares to Backstop Parties in payment of the five percent backstop fee ($1,764,240) payable to the Backstop Parties in connection with the Backstop Agreement entered into between the Company and the Backstop Parties. When shares were issued to the Backstop Parties in payment of the backstop fee, the stock price of SIGA common stock was $2.49 per share (the closing price of the Company’s common stock on November 16, 2016). The fair value of the shares issued in satisfaction of the backstop fee has been expensed on the income statement in 2016. There are no remaining payment obligations to the Backstop Parties under the Backstop Agreement.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Significant Accounting Policies	Summary of Significant Accounting Policies Use of Estimates The consolidated financial statements and related disclosures are prepared in conformity with accounting principles generally accepted in the United States of America. Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and revenue and expenses during the period reported. The most significant estimates include the variables used in the calculation of fair value of stock-based awards including options and warrants granted or issued by the Company; reported amounts of revenue; calculation of contingencies; and the realization of deferred tax assets. Estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the financial statements in the period they are determined to be necessary. Actual results could differ from these estimates. Basis of presentation The consolidated financial statements are presented in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) and reflect the consolidated financial position, results of operations and cash flows for all periods presented. Cash Equivalents The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. Restricted Cash and Cash Equivalents A portion of the Company’s cash received under the Loan Agreement is restricted. In accordance with the Loan Agreement, cash placed in the reserve account is restricted. Except for $5 million , cash in the reserve account can only be utilized to pay interest on the Term Loan. The aforementioned $5 million in the reserve account can be withdrawn after June 30, 2018 upon the satisfaction of certain conditions. As of December 31, 2016, the restricted cash balance was $27.5 million of which $10.1 million is designated as a current asset and the remainder is designated as non-current. See Note 7 to the financial statements for additional information. Concentration of Credit Risk The Company has cash in bank accounts that exceed the Federal Deposit Insurance Corporation insured limits. The Company has not experienced any losses on its cash accounts and no allowance has been provided for potential credit losses because management believes that any such losses would be minimal, if any. Accounts Receivable Accounts receivable are recorded net of provisions for doubtful accounts. At December 31, 2016 and 2015 , 100% of accounts receivables represented receivables from Biomedical Advanced Research and Development Authority (“BARDA”) and National Institutes of Health (“NIH”). An allowance for doubtful accounts is based on specific analysis of the receivables. At December 31, 2016 and 2015 , the Company had no allowance for doubtful accounts. Inventory Inventories are stated at the lower of cost or estimated realizable value. The Company capitalizes inventory costs associated with the Company’s products when, based on management’s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed as research and development. Inventory is evaluated for impairment periodically to identify inventory that may expire prior to expected sale or has a cost basis in excess of its estimated realizable value. If certain batches or units of product no longer meet quality specifications or become obsolete due to expiration, the Company records a charge to write down such unmarketable inventory to its estimated realizable value. Property, Plant and Equipment Property, plant and equipment are stated at cost, net of accumulated depreciation. Depreciation is provided on a straight-line method over the estimated useful lives of the various asset classes. The estimated useful lives are as follows: 5 years for laboratory equipment; 3 years for computer equipment; and 7 years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the estimated useful lives of the assets or the lease term. Maintenance, repairs and minor replacements are charged to expense as incurred. Warrant Liability The Company accounts for warrants in accordance with the authoritative guidance which requires that free-standing derivative financial instruments with certain anti-dilution features be classified as assets or liabilities at the time of the transaction, and recorded at their fair value. Fair value is estimated using model-derived valuations. Any changes in the fair value of the derivative instruments are reported in earnings or loss as long as the derivative contracts are classified as assets or liabilities. Revenue Recognition Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed or determinable, collectability is reasonably assured, title and risk of loss have been transferred to the customer and there are no further contractual obligations. Certain arrangements may provide for multiple deliverables, in which there may be a combination of: up-front licenses; research, development, regulatory or other services; and delivery of product. Multiple deliverable arrangements can be divided into separate units of accounting if the deliverables in the arrangement meet the following criteria: (i) the delivered item(s) have value to the customer on a standalone basis and (ii) in circumstances in which an arrangement includes a general right of return with respect to delivered items, then performance of the remaining deliverables must be considered probable and substantially in control of the Company. If multiple deliverables cannot be divided into separate units of accounting then the deliverables must be combined into a single unit of accounting. Total consideration in a multiple deliverable arrangement is allocated to units of accounting on a relative fair value of selling price basis. Consideration allocated to a delivered item or unit of accounting is limited to the amount that is not contingent upon delivery of additional items. Direct costs incurred by the Company and associated with the deferral of revenue for a unit of accounting will also be deferred and will be recognized as expenses over the same period that the related deferred revenue is recognized as revenue. Subject to the above, payments for development activities are recognized as revenue when earned, over the period of effort. Funding for the acquisition of capital assets under cost-plus-fee contracts or grants is evaluated for appropriate recognition as a reduction to the cost of the asset, a financing arrangement, or revenue based on the specific terms of the related grant or contract. For the years ended December 31, 2016 , 2015 , and 2014 , revenues from BARDA and NIH were 100% of total revenues recognized by the Company. Research and Development Research and development expenses include costs directly and indirectly attributable to the conduct of research and development programs, and performance of the BARDA Contract, including employee related costs, materials, supplies, depreciation on and maintenance of research equipment, the cost of services provided by outside contractors, including services related to the Company’s clinical trials and facility costs, such as rent, utilities, and general support services. All costs associated with research and development are expensed as incurred. Costs related to the acquisition of technology rights, for which development work is still in process, and that have no alternative future uses, are expensed as incurred. Goodwill The Company evaluates goodwill for impairment at least annually or as circumstances warrant. The impairment review process compares the fair value of the reporting unit in which goodwill resides to its carrying value. The Company operates as one business and one reporting unit. Therefore, the goodwill impairment analysis is performed on the basis of the Company as a whole, using the market capitalization of the Company as an estimate of its fair value. Share-based Compensation Stock-based compensation expense for all share-based payment awards made to employees and directors is determined on the grant date; for options awards, fair value was estimated using the Black-Scholes model and for stock appreciation rights (“SARs”), fair value was estimated using the Monte Carlo method. The value of the portion of the award that is ultimately expected to vest is recorded as expense over the requisite service periods in the Company’s consolidated statement of operations. These compensation costs are recognized net of an estimated forfeiture rate over the requisite service periods of the awards. Forfeitures are estimated on the date of the respective grant and revised if actual or expected forfeiture activity differs from original estimates. Income Taxes The Company recognizes income taxes utilizing the asset and liability method of accounting for income taxes. Under this method, deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities at enacted tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is established if it is more likely than not that some or the entire deferred tax asset will not be realized. The recognition of a valuation allowance for deferred taxes requires management to make estimates and judgments about the Company’s future profitability which are inherently uncertain. Net Loss per Share The objective of basic earnings per share (“EPS”) is to measure the performance of an entity over the reporting period by dividing income (loss) by the weighted average shares outstanding. The objective of diluted EPS is consistent with that of basic EPS, except that it also gives effect to all potentially dilutive common shares outstanding during the period. The Company incurred losses for the years ended December 31, 2016 , 2015 and 2014 . For all periods presented, all equity instruments are excluded from the calculation of diluted earnings (loss) per share as the effect of such shares is anti-dilutive. The weighted average number of equity instruments excluded consist of: Year Ended December 31, 2016 2015 2014 Stock Options 1,789,751 2,047,083 2,179,643 Stock-Settled Stock Appreciation Rights 360,031 368,331 388,325 Restricted Stock Units 705,850 700,265 1,206,534 Warrants 877,303 82,192 772,903 As discussed in Note 6, the appreciation of each SSAR was capped at a determined maximum value. As a result, the weighted average number shown in the table above for stock-settled stock appreciation rights reflects the weighted average maximum number of shares that could be issued. Fair Value of Financial Instruments The carrying value of cash and cash equivalents, restricted cash and cash equivalents, accounts payable and accrued expenses approximates fair value due to the relatively short maturity of these instruments. Common stock warrants which are classified as liabilities are recorded at their fair market value as of each reporting period. The measurement of fair value requires the use of techniques based on observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our market assumptions. The inputs create the following fair value hierarchy: • Level 1 – Quoted prices for identical instruments in active markets. • Level 2 – Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations where inputs are observable or where significant value drivers are observable. • Level 3 – Instruments where significant value drivers are unobservable to third parties. The Company uses model-derived valuations where certain inputs are unobservable to third parties to determine the fair value of certain common stock warrants on a recurring basis and classify such liability classified warrants in Level 3. On September 2, 2016, the date of issuance of the current liability classified warrant, the Company used a Monte Carlo simulation model to calculate the fair market value of the warrant.The Company compared the Monte Carlo simulation model calculation to a Black-Scholes model calculation. These models generated substantially equal values. As such, the Company utilized a Black-Scholes model for December 31, 2016, consisting of the following variables: (i) the closing price of SIGA’s common stock; (ii) the expected remaining life of the liability classified warrant; (iii) the expected volatility using a weighted-average of historical volatilities from a combination of SIGA and comparable companies; and (iv) the risk-free market rate. At December 31, 2016, the fair value of liability classified warrant is $6.7 million At December 31, 2016, the fair value of the debt was $69.9 million and the carrying value of the debt was $66.6 million . The Company used a discounted cash flow model to estimate the fair value of the debt by applying a discount rate to future payments expected to be made as set forth in the Loan Agreement. The fair value of the loan was measured using level 3 inputs. The discount rate was determined using market participant assumptions. This valuation required significant judgment. There were no transfers between levels of the fair value hierarchy during 2016. The following table presents changes in the liability classified warrant measured at fair value using Level 3 inputs: Fair Value Measurements of Level 3 liability classified warrant Warrant liability at September 02, 2016 - issuance date $ 5,832,624 Increase in fair value of warrant liability 894,785 Warrant liability at December 31, 2016 $ 6,727,409 Legal Contingencies The Company is subject to certain contingencies arising in the ordinary course of business. The Company records accruals for these contingencies to the extent that a loss is both probable and reasonably estimable. If some amount within a range of loss appears to be a better estimate than any other amount within the range, that amount is accrued. Alternatively, when no amount within a range of loss appears to be a better estimate than any other amount, the lowest amount in the range is accrued. The Company expenses legal costs associated with loss contingencies as incurred. We record anticipated recoveries under existing insurance contracts when recovery is assured. Segment Information The Company is managed and operated as one business. The entire business is managed by a single management team that reports to the chief executive officer. The Company does not operate separate lines of business or separate business entities with respect to any of its product candidates. Accordingly, the Company does not prepare discrete financial information with respect to separate product areas or by location and only has one reportable segment. Recent Accounting Pronouncements On November 17, 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, a consensus of the FASB’s Emerging Issues Task Force. The new standard requires that the statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Entities will also be required to reconcile such total to amounts on the balance sheet and disclose the nature of the restrictions. The standard is effective for financial statements issued for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The guidance requires application using a retrospective transition method. The Company is currently evaluating the impact that ASU 2016-18 will have on its consolidated financial statements. On August 26, 2016, the FASB issued ASU 2016­ -15, Statement of Cash Flows (Topic 230), a consensus of the FASB’s Emerging Issues Task Force. The new guidance is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. The standard is effective for financial statements issued for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, provided that all of the amendments are adopted in the same period. The guidance requires application using a retrospective transition method. The Company is currently evaluating the impact that ASU 2016-15 will have on its consolidated financial statements. In March 2016, the FASB amended the existing accounting standards for stock-based compensation, ASU 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendments impact several aspects of accounting for share-based payment transactions, including the income tax consequences, forfeitures, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The Company is required to adopt the amendments in the first quarter of 2017, with early adoption permitted. If early adoption is elected, all amendments must be adopted in the same period. The manner of application varies by the various provisions of the guidance, with certain provisions applied on a retrospective or modified retrospective approach, while others are applied prospectively. The Company assessed the impact of ASU 2016-09 and believes adoption of the ASU will not have a material impact on its consolidated financial statements. On February 25, 2016, the FASB issued ASU 2016-02 Leases, which relates to the accounting of leasing transactions. This standard requires a lessee to record on the balance sheet the assets and liabilities for the rights and obligations created by leases with lease terms of more than 12 months. In addition, this standard requires both lessees and lessors to disclose certain key information about lease transactions. This standard will be effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact that ASU 2016-02 will have on its consolidated financial statements. In August 2014, the FASB issued Accounting Standard Update ( “ ASU ” ) No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40) Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern . This ASU requires management to assess whether there is substantial doubt about the entity’s ability to continue as a going concern and, if so, disclose that fact. Management will also be required to evaluate and disclose whether its plans alleviate that doubt. This ASU states that, when making this assessment, management should consider relevant conditions or events that are known or reasonably knowable on the date the financial statements are issued or available to be issued. This ASU is effective for annual periods ending after December 15, 2016 and interim periods thereafter, and early adoption is permitted. The Company adopted ASU 2014-15 and for adoption impact see Note 1 to the financial statements under "liquidity". In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) . ASU No. 2014-09 supersedes the revenue recognition requirements in Topic 605, Revenue Recognition , and most industry-specific revenue recognition guidance throughout the Industry Topics of the Accounting Standards Codification. Additionally, this update supersedes some cost guidance included in Subtopic 605-35, Revenue Recognition-Construction-Type and Production-Type Contracts . The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. It is effective for the first interim period within annual reporting periods beginning after December 15, 2017, and early adoption is permitted for the first interim periods beginning after December 15, 2016. The Company is assessing the potential impact of the variable consideration related to milestones and other payments received as well as the impact of the potential replacement obligation for courses already delivered to BARDA. The Company will continue to assess the impact of ASU 2014-09.

Procurement Contract and Resear

Procurement Contract and Research Agreements	12 Months Ended
	Dec. 31, 2016
Research and Development [Abstract]
Procurement Contract and Research Agreements	Procurement Contract and Research Agreements Procurement Contract On May 13, 2011, the Company signed a contract with the U.S. Biomedical Advanced Research and Development Authority ("BARDA") pursuant to which SIGA agreed to deliver two million courses of TPOXX® to the U.S. Strategic National Stockpile (“Strategic Stockpile”). The contract with BARDA (as modified, the "BARDA Contract") is worth approximately $472 million , including $409.8 million related to the manufacture and delivery of 1.7 million courses of TPOXX® and $62 million of potential reimbursements connected to development and supportive activities (the “Base Contract”). Under the Base Contract, BARDA has agreed to buy from the Company 1.7 million courses of TPOXX®. Additionally, the Company expects to contribute to BARDA 300,000 courses at no additional cost to BARDA. A total of 2.0 million courses of TPOXX® is required to be delivered to the Strategic Stockpile in order for the Company to receive the $41 million hold back payment (see description of hold back payment below). For courses of TPOXX® that are physically delivered to the Strategic Stockpile, the Company has replacement obligations, at no cost to BARDA, in the event that the final version of TPOXX® approved by the U.S. Food and Drug Administration (the "FDA") is different from any courses of TPOXX® that has been delivered to the Strategic Stockpile or if TPOXX® does not meet any specified label claims, fails release testing or does not meet 38 month expiry period (from time of delivery to the Strategic Stockpile), or if TPOXX® is recalled or deemed to be recalled for any reason. On June 28, 2016, the Company entered into a modification of the BARDA Contract (the "BARDA Contract Modification"). The total value of the BARDA Contract is unchanged. Pursuant to the BARDA Contract Modification: • The payment for the manufacture and delivery of 1.7 million courses of TPOXX® increased by $61.5 million . This was accomplished by reducing the holdback amount that is tied to the United States Food & Drug Administration (the "FDA") approval of TPOXX® from $102.5 million to $41 million . In July 2016, the Company received payment of $32.6 million in connection with the BARDA Contract Modification for courses previously delivered to the Strategic Stockpile. • The requirements for the $20.5 million milestone changed. For payment, this milestone was modified to require the Company to submit documentation to BARDA indicating that data covering the first 100 subjects enrolled in the phase III pivotal safety study have been submitted to and reviewed by a Data & Safety Monitoring Board ("DSMB") and that such DSMB has recommended continuation of the safety study, as well as submission of the final pivotal rabbit efficacy study report to the FDA. Previously, this milestone required the successful submission to the FDA of a complete application for TPOXX® regulatory approval. During the third quarter of 2016, the Company met the modified milestone and received payment. As of December 31, 2016, the Company has received $360.4 million under the Base Contract related to the manufacture and physical delivery of courses of TPOXX®. Included in this amount are a $41 million advance payment in 2011 for the completion of certain planning and preparatory activities related to the Base Contract, a $12.3 million milestone payment in 2012 for the completion of the product labeling strategy for TPOXX®, an $8.2 million milestone payment in 2013 for the completion of the commercial validation campaign for TPOXX®, the $20.5 million milestone payment (referenced above) in 2016 for submission of documentation to BARDA indicating that data covering the first 100 subjects enrolled in the phase III pivotal safety study have been submitted to and reviewed by a DSMB and that such DSMB has recommended continuation of the safety study, as well as submission of the final pivotal rabbit efficacy study report to the FDA, and $278.4 million of payments for physical deliveries of TPOXX® to the Strategic Stockpile beginning in 2013. As of December 31, 2016, the Company was eligible to receive an additional $49.4 million under the Base Contract for the manufacture, delivery and purchase by BARDA of courses of TPOXX®. Included in this amount are: $8.5 million of payments related to physical deliveries of TPOXX® to the Strategic Stockpile; and a $41 million hold back payment, which represents an approximate 10% hold back on the $409.8 million of total payments related to the manufacture and delivery of 1.7 million courses of TPOXX® that are to be purchased by BARDA. The $41 million hold back payment would be triggered by FDA approval of TPOXX®, as long as the Company has cumulatively delivered 2.0 million courses of TPOXX® to the Strategic Stockpile and the Company does not have a continuing product replacement obligation to BARDA. In February 2017, the Company received an $8.5 million payment for a product delivery made in January 2017 of TPOXX® courses. With regard to future product deliveries after February 28, 2017, the Company expects to deliver approximately 467,000 courses of TPOXX® at no cost to BARDA in order to fulfill the delivery requirements of the BARDA Contract. Courses to be delivered are expected to be at a dosage of 600 mg administered twice per day (1,200 mg per day). The “no cost to BARDA” courses are attributable to a change in TPOXX® dosage (see paragraph below). Courses delivered to the Strategic Stockpile are subject to a product replacement obligation. Starting in 2015, product deliveries of TPOXX® have been at a provisional dosage of 600 mg administered twice per day (1,200 mg per day). This is a change from the provisional dosage that was in effect when product deliveries were made in 2013 and 2014 (600 mg per day). In 2013 and 2014, the provisional dosage of courses delivered to the Strategic Stockpile was 600 mg administered once a day. The change in the provisional dosage was based on FDA guidance received by the Company in 2014, subsequent to the delivery of 1.3 million courses of TPOXX®. Based on the current provisional dosage of 600 mg administered twice per day (1,200 mg per day), the Company expects to supplement previously delivered courses of TPOXX®, at no cost to BARDA, with additional dosages so that all of the courses previously delivered to BARDA will be at the current provisional dosage. The Company and BARDA agreed to an amendment (the “BARDA Amendment”) of the BARDA Contract to reflect the foregoing. In February 2016, the FDA confirmed (through dose concurrence) its earlier dosage guidance of 600 mg administered twice per day (1,200 mg per day). The Company is incurring significant incremental costs with the production of additional dosage at no cost to BARDA. In addition to the Base Contract, the BARDA Contract also separately contains $122.7 million of options that, if exercised by BARDA: would result in a $50 million payment to the Company in the event of FDA approval for extension to 84-month expiry for TPOXX® (from 38 month expiry as required in the Base Contract); would fund up to $58.3 million of development and supportive activities such as work on a smallpox prophylaxis indication for TPOXX®; and/or would fund $14.4 million of production-related activities related to warm-base manufacturing. In 2015, BARDA exercised two options related to extending the indication of the drug to the geriatric and pediatric populations. The stated value of these exercises was minimal. BARDA may not exercise additional options in the future. Options are exercisable by BARDA at its sole discretion. BARDA has indicated that it will evaluate, after the FDA’s review and evaluation of stability data, the Company's request that BARDA exercise the option for the $50 million payment to the Company in the event of FDA approval of 84-month expiry for TPOXX®. The BARDA Contract expires in September 2020. The BARDA Contract is a multiple deliverable arrangement comprising delivery of courses and covered research and development activities. The BARDA Contract provides certain product replacement rights with respect to delivered courses. For this reason, recognition of revenue that might otherwise occur upon delivery of courses is expected to be deferred until the Company’s obligations related to potential replacement of delivered courses are satisfied. The Company assessed the selling price for each of the aforementioned deliverables - research and development activities and drug product. The selling price of certain reimbursed research and development services was determined by reference to existing and past research and development grants and contracts between the Company and various government agencies. The selling price of drug product was determined by reference to other Companies’ sales of drug products such as antiviral therapeutics, orphan drugs and drugs with potential life-saving impact similar to TPOXX®, including products delivered to the Strategic Stockpile. The Company has recognized revenue for reimbursement of certain BARDA Contract research and development services. Cash inflows related to delivery of courses will continue to be recorded as deferred revenue. In addition, direct costs incurred by the Company to fulfill the delivery of courses including the supplementing of courses previously delivered under the BARDA Contract are being deferred and will be recognized as expenses over the same period that the related deferred revenue is recognized as revenue. As of December 31, 2016 and 2015, deferred direct costs under the BARDA Contract of approximately $72.2 million and $52.5 million , respectively, are included in deferred costs on the consolidated balance sheets. As of December 31, 2016, the Company recorded $367.4 million of deferred revenue. Deferred revenue has been recorded for the delivery of courses of TPOXX® to the Strategic Stockpile and certain supportive services provided as part of the BARDA Contract. For the year ended December 31, 2016, revenue from reimbursed research and development was $13.2 million . Research Agreements The Company obtains funding from the contracts and grants it obtains from various agencies of the U.S. Government to support its research and development activities. Currently, the Company has one contract and one grant with varying expiration dates through February 2018 that provide for potential future aggregate research and development funding for specific projects of approximately $18.0 million. We may not utilize all available funds under the contract and/or grant. The funded amount includes, among other things, options that may or may not be exercised at the U.S. government’s discretion. Moreover, the contract and grant contain customary terms and conditions including the U.S. Government’s right to terminate or restructure a grant for convenience at any time.

Liabilities Subject to Compromi

Liabilities Subject to Compromise	12 Months Ended
	Dec. 31, 2016
Liabilities Subject to Compromise [Abstract]
Liabilities subject to compromise	Liabilities Subject to Compromise Liabilities Subject to Compromise represented the Company's estimate, where an estimate was determinable, of known or potential pre-petition claims to be addressed in connection with its chapter 11 case. Subsequent to emergence from chapter 11 of the Bankruptcy Code on April 12, 2016, the Company paid all of its Liabilities Subject to Compromise (prepetition liabilities) in accordance with the Plan. As of December 31, 2016 and 2015, Liabilities Subject to Compromise consisted of the following: December 31, 2016 December 31, 2015 Accounts payable - pre-petition $ — $ 834,219 Accrual- PharmAthene Litigation — 205,400,068 (1 ) Other accrued expenses - pre-petition — 737,883 Total $ — $ 206,972,170 (1) Includes a $3.2 million accrual at December 31, 2015 for reimbursement of PharmAthene attorney's fees and expert fees, against which there is a $2.7 million surety bond that has cash collaterization of $1.3 million . In 2016, the Company received the $1.2 million of cash collaterization from a surety bond upon satisfaction of the PharmAthene claim. Reorganization Items, net: Reorganization items represents expenses in connection with the chapter 11 case. Subsequent to emergence from chapter 11 of the Bankruptcy Code on April 12, 2016, $684,000 of expenses that are related to the implementation of the Plan are reported in selling, general and administrative. As of December 31, 2016 and 2015, reorganization items consisted of the following: December 31, 2016 December 31, 2015 Legal fees $ 1,951,381 $ 5,719,052 Professional fees 1,732,521 2,027,827 Trustee fees 33,000 59,000 Other — 5,672 Total $ 3,716,902 $ 7,811,551 The cash payments for the reorganization items for the years-ended December 31, 2016 and 2015 were $4.6 million and $6.7 million , respectively.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2016
Equity [Abstract]
Stockholders' Equity	Stockholders’ Equity On December 31, 2016 , the Company’s authorized share capital consisted of 620,000,000 shares, of which 600,000,000 are designated common shares and 20,000,000 are designated preferred shares. The Company’s Board of Directors is authorized to issue preferred shares in series with rights, privileges and qualifications of each series determined by the Board. As of December 31, 2016 and 2015 , no preferred shares were outstanding or issued. Rights Offering On November 16, 2016, the Company completed a rights offering (the “Rights Offering”), pursuant to which it raised approximately $35.3 million in gross proceeds through the sale of 23,523,195 shares of its common stock. The Rights Offering was made pursuant to a registration statement on Form S-1 filed with the Securities and Exchange Commission (the “SEC”) and declared effective by the SEC on October 21, 2016. As part of the Rights Offering, each stockholder of the Company received one subscription right for each share of common stock owned as of the record date of October 12, 2016. Each subscription right entitled its holder to invest $0.65 towards the purchase of shares of the Company's common stock at a subscription price equal to the lower of $1.50 or 85% of the volume weighted average price of Company shares during market hours on the expiration date of the Rights Offering. The Rights Offering expired at 5:00 pm, New York City time, on November 8, 2016. Through basic subscriptions and oversubscriptions, the Rights Offering was fully subscribed. The subscription price was set at $1.50 . The Company used the net proceeds of the Rights Offering, together with proceeds from the Loan Agreement and cash on hand, to fully satisfy PharmAthene's claim under the Plan. Rights Offering - Backstop Agreement On October 13, 2016, in connection with the Rights Offering as discussed above, the Company entered into an investment agreement or "backstop agreement," with M&F, and other backstop parties (the "Backstop Parties"). Under the term of the backstop agreement, the Backstop Parties agreed to purchase, pursuant to a separate private placement, a number of shares of common stock equal to the numbers of shares that would have not been subscribed for in the Rights Offering. Under the backstop agreement, the subscription price was set to be equal to the subscription price applicable to all shareholders under the Rights Offering. The Rights Offering was fully subscribed, the Backstop Parties were not required to draw on such commitment. The Company issued 708,530 shares to Backstop Parties in payment of the five percent backstop fee ($1,764,240) payable to the Backstop Parties in connection with the backstop agreement entered into between the Company and the Backstop Parties. When shares were issued to the Backstop Parties in payment of the backstop fee, the stock price of SIGA common stock was $2.49 per share (the closing price of the Company’s common stock on November 16, 2016). The fair value of the shares issued in satisfaction of the backstop fee has been expensed on the income statement in 2016. There are no remaining payment obligations to the Backstop Parties under the Backstop Agreement. 2016 Warrant On September 2, 2016, in connection with the entry into the Loan Agreement (see Note 7 to the financial statements for additional information), the Company issued a warrant (the "Warrant") to the Lender to purchase a number of shares of the Company’s common stock equal to $4,000,000 divided by the lower of (i) $2.29 per share and (ii) the subscription price paid in connection with the Rights Offering. The Warrant provides for weighted average anti-dilution protection and is exercisable in whole or in part for ten ( 10 ) years from the date of issuance. The subscription price paid was $1.50 in connection with the Rights Offering; accordingly, the exercise price of the Warrant has been set at $1.50 per share. The Company accounted for the Warrant in accordance with the authoritative guidance which requires that free-standing derivative financial instruments with certain anti-dilution features be classified as assets or liabilities at the time of the transaction, and recorded at their fair value. Any changes in the fair value of the derivative instruments are reported in earnings or loss as long as the derivative contracts are classified as assets or liabilities. Accordingly, the Company classified the Warrant as a liability and reported the change in fair value in the statement of operations. On September 2, 2016, the issuance date of the Warrant, the fair value of the liability classified Warrant was $5.8 million . The Company applied a Monte Carlo Simulation-model to calculate the fair value of the liability classified Warrant using the following assumptions: risk free interest rate of 1.60% ; no dividend yield; an expected life of 10 years; and a volatility factor of 80% . The Company compared the Monte Carlo simulation model calculation to a Black-Scholes model calculation. These models generated substantially equal fair values for the Warrant. As such, the Company utilized a Black-Scholes model for December 31, 2016 to determine the fair value of the Warrant. As of December 31, 2016, the fair value of the Warrant was $6.7 million . A Black Scholes model was applied to calculate the fair value of the liability classified Warrant using the following assumptions: risk free interest rate of 2.44% ; no dividend yield; an expected life of 9.67 years; and a volatility factor of 80% . For the year-ended December 31, 2016, the Company recorded a loss of $895,000 as a result of a net increase in fair value in the liability classified Warrant since its issuance on September 2, 2016.

Stock Compensation Plans

Stock Compensation Plans	12 Months Ended
	Dec. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Compensation Plans	Stock Compensation Plans The Company’s 2010 Stock Incentive Plan (the “2010 Plan”) was initially adopted in May 2010. The 2010 Plan provided for the issuance of stock options, restricted stock and unrestricted stock with respect to an aggregate of 2,000,000 shares of the Company’s Common Stock to employees, consultants and outside directors of the Company. On May 17, 2011, the 2010 Plan was amended to provide for the issuance of restricted stock units (“RSUs”) and on February 2, 2012, the 2010 Plan was amended to provide for the issuance of SARs. Effective April 25, 2012, the 2010 Plan was amended to increase the maximum number of shares of Common Stock available for issuance to an aggregate of 4,500,000 shares. The vesting period for awards granted under the 2010 Plan, is determined by the Compensation Committee of the Board of Directors. The Compensation Committee also determines the expiration date of each equity award, however, stock options and SARs may not be exercisable more than ten years after the date of grant as the maximum term of equity awards issued under the 2010 Plan is ten years. For the years ended December 31, 2016 , 2015 and 2014 , the Company recorded stock-based compensation expense, including stock options, SARs, RSUs and certain warrant amortization, of approximately $775,541 , $1.6 million and $2.4 million , respectively. Stock Options Stock option awards provide holders the right to purchase shares of Common Stock at prices determined by the Compensation Committee and must have an exercise price equal to or in excess of the fair market value of the Company’s common stock at the date of grant. There were no stock options granted during the years-ended 2016 and 2015 . The fair value of options granted prior to December 31, 2015 were estimated at the date of grant. Expected volatility has been estimated using a combination of the Company’s historical volatility and the historical volatility of a group of comparable companies, both using historical periods equivalent to the options’ expected lives. The expected dividend yield assumption is based on the Company’s intent not to issue a dividend in the foreseeable future. The risk-free interest rate assumption is based upon observed interest rates for securities with maturities approximating the options’ expected lives. The expected life was estimated based on historical experience and expectation of employee exercise behavior in the future giving consideration to the contractual terms of the award. A summary of the Company’s stock option activity is as follows: Number of Options Weighted Average Exercise Price Weighted Average Remaining Life (in years) Aggregate Intrinsic Value (in thousands) Outstanding at January 1, 2016 1,924,967 $ 4.51 Granted — — Exercised — — Canceled/Expired (215,000 ) 2.47 Outstanding at December 31, 2016 1,709,967 $ 4.76 1.96 $ — Vested and expected to vest at December 31, 2016 1,709,967 $ 4.76 1.96 $ — Exercisable at December 31, 2016 1,709,967 $ 4.76 1.96 $ — As of December 31, 2016 , $4,000 of total remaining unrecognized stock-based compensation cost related to stock options is expected to be recognized over the weighted-average remaining requisite service period of 0.5 years . The total fair value of vested stock options was $0 , $0 and $144,000 for the years ended December 31, 2016 , 2015 and 2014 , respectively. The total intrinsic value of stock options exercised was $0 , $5,900 and $19,000 for the years ended December 31, 2016 , 2015 and 2014 , respectively. The intrinsic value represents the amount by which the market price of the underlying stock exceeds the exercise price of an option. As of December 31, 2016 and 2015 , 200,000 of the Company’s outstanding options, were subject to specific performance conditions consisting of regulatory approval of our lead drug candidate. Stock Appreciation Rights Stock-settled stock appreciation rights (“SSARs”) provide holders the right to purchase shares of Common Stock at prices determined by the Compensation Committee and must have an exercise price equal to or in excess of the fair market value of the Company’s common stock at the date of grant. Upon exercise, the gain, or intrinsic value, is settled by the delivery of SIGA stock to the employee. There were no SSARs granted during the years ended 2016 and 2015. During the year ended December 31, 2012, the Company granted 1.4 million shares of SSARs at a weighted average grant-date fair value of $0.68 per share. The exercise price of a SSAR is equal to the closing market price on the date of grant. The granted SSARs vest in equal annual installments over a period of three years and expire no later than seven years from the date of grant. Moreover, the appreciation of each SSAR was capped at a determined maximum value. At December 31, 2016 and 2015 , due to the cap on value the maximum number of shares that could be issued in the future was 360,031 and 365,689 , respectively. The fair value of granted SSARs has been estimated utilizing a Monte Carlo method. The Monte Carlo method is a statistical simulation technique used to provide the grant-date fair value of an award. As the issued SSARs were capped at maximum values, such attribute was considered in the simulation. The Company calculates the expected volatility using a combination of SIGA’s historical volatility and the volatility of a group of comparable companies. The expected life from grant date was estimated based on the expectation of exercise behavior in consideration of the maximum value and contractual term of the SSARs. The dividend yield assumption is based on the Company’s intent not to issue a dividend in the foreseeable future. The risk-free interest rate assumption is based upon observed interest rates appropriate for the expected life of the SSARs. A summary of the Company’s SSAR activity is as follows: Number of SSARs Weighted Average Exercise Price Weighted Average Remaining Life (in years) Aggregate Intrinsic Value (in thousands) Outstanding at January 1, 2016 1,209,274 $ 3.53 Granted — — Exercised — — Canceled/Expired (26,250 ) 3.53 Outstanding at December 31, 2016 1,183,024 $ 3.53 2.09 $ — Vested and expected to vest at December 31, 2016 1,183,024 $ 3.53 2.09 $ — Exercisable at December 31, 2016 1,183,024 $ 3.53 2.09 $ — The total fair value of vested SSARs was $0 , $0 and $267,000 for the years ended December 31, 2016, 2015 and 2014, respectively. Restricted Stock Awards/Restricted Stock Units RSUs awarded to employees vest in equal annual installments over a three-year period and RSUs awarded to directors of the Company vest over a one-year period. A summary of the Company’s RSU activity is as follows: Number of RSUs Weighted Average Grant-Date Fair Value Outstanding at January 1, 2016 661,671 $ 2.96 Granted 1,302,353 2.24 Vested (483,335 ) 2.81 Canceled/Expired (25,000 ) 3.35 Outstanding at December 31, 2016 1,455,689 $ 2.36 As of December 31, 2016 , $ 2.8 million of total remaining unrecognized stock-based compensation cost related to RSUs is expected to be recognized over the weighted-average remaining requisite service period of 2.38 years. The weighted average fair value at the date of grant for restricted stock awards granted during the years ended December 31, 2016, 2015 and 2014 was $2.24 , $2.00 and $3.23 per share, respectively. Based on the grant date, the total fair value of restricted stock and restricted stock units vested during the years ended December 31, 2016, 2015 and 2014 was $1.4 million , $1.8 million and $1.5 million .

Debt

Debt	12 Months Ended
	Dec. 31, 2016
Debt Disclosure [Abstract]
Debt	Debt On September 2, 2016, the Company entered into a loan and security agreement (as amended from time to time, the “Loan Agreement”) with OCM Strategic Credit SIGTEC Holdings, LLC (“Lender”), pursuant to which the Company received $80 million on November 16, 2016 having satisfied certain pre-conditions. Proceeds related to the Loan Agreement ( $80 million ) had been placed in an escrow account on September 30, 2016 (the “Escrow Funding Date”). Prior to the Escrow Release Date (November 16, 2016), the Company did not have access to, or any ownership interest in, the escrow account. Until the Escrow Release Date occurred, the Company did not have an obligation to make any payments under the Loan Agreement, no security was granted under the Loan Agreement and no affirmative or negative covenants or events of default were effective under the Loan Agreement. Amounts were held in the escrow account until the satisfaction of certain conditions including the closing of the Rights Offering on November 16, 2016. Amounts held in the escrow account between September 30, 2016 and November 15, 2016 bore interest at a per annum rate equal to the Adjusted LIBOR Rate (as defined in the Loan Agreement) plus 11.50% . Interest on amounts held in the escrow account became payable only when the Escrow Release Date occurred. As part of the satisfaction of the PharmAthene claim, funds were released from the escrow account (the date on which such transfer occurred, the “Escrow Release Date”). The Loan Agreement provides for a first-priority senior secured term loan facility in the aggregate principal amount of $80,000,000 (the “Term Loan”), of which (i) $25,000,000 was placed in a reserve account (the “Reserve Account”) only be utilized to pay interest on the Term Loan as it becomes due; (ii) an additional $5,000,000 was also placed in the Reserve Account and up to the full amount of such $5,000,000 may be withdrawn after June 30, 2018 upon the satisfaction of certain conditions, provided that any of such amount is required to fund any interest to the extent any interest in excess of the aforementioned $25,000,000 is due and owing and any of such $5,000,000 remains in the Reserve Account; and (iii) $50,000,000 (net of fees and expenses then due and owing to the Lender) was paid to PharmAthene as part of the final payment to satisfy the PharmAthene claim. Interest on the Term Loan is at a per annum rate equal to the Adjusted LIBOR rate plus 11.50% , subject to adjustments as set forth in the Loan Agreement. At December 31, 2016, the effective interest rate on the Term Loan was 18.30% . The Company incurred approximately $1.8 million of interest expense during the year-ended December 31, 2016, of which $1.2 million was paid from restricted cash. The Term Loan shall mature on the earliest to occur of (i) the four year anniversary of the Escrow Release Date, and (ii) the acceleration of certain obligations pursuant to the Loan Agreement. At maturity, $80 million of principal will be repaid, and an additional $4 million will be paid (see below). Prior to maturity, there are no scheduled principal payments. Through the three and one-half year anniversary of the Escrow Release Date, any prepayment of the Term Loan is subject to a make-whole provision in which interest payments related to the prepaid amount are due (subject to a discount of treasury rate plus 0.50% ). In connection with the Term Loan, the Company has granted the Lender a lien on and security interest in all of the Company’s right, title and interest in substantially all of the Company’s tangible and intangible assets, including all intellectual property. The Loan Agreement contains customary representations and warranties and customary affirmative and negative covenants. These covenants, among other things, require a minimum cash balance throughout the term of the Term Loan and the achievement of regulatory milestones by certain dates, and contain certain limitations on the ability of the Company to incur unreimbursed research and development expenditures over a certain threshold, make capital expenditures over a certain threshold, incur indebtedness, dispose of assets outside of the ordinary course of business and enter into certain merger or consolidation transactions. The aforementioned minimum cash requirement will be $15 million until June 30, 2017 and will reduce to $10 million for the remainder of 2017 and reduce to $5 million for 2018 until the earlier of (i) December 31, 2018 and (ii) 45 days after FDA approval of TPOXX®; thereafter, the minimum cash requirement will be $20 million . The Loan Agreement includes customary events of default, including, among others: (i) non-payment of amounts due thereunder, (ii) the material inaccuracy of representations or warranties made thereunder, (iii) non-compliance with covenants thereunder, (iv) non-payment of amounts due under, or the acceleration of, other material indebtedness of the Company and (v) bankruptcy or insolvency events. Upon the occurrence and during the continuance of an event of default under the Loan Agreement, the interest rate may increase by 2.00% per annum above the rate of interest otherwise in effect, and the Lenders would be entitled to accelerate the maturity of the Company’s outstanding obligations thereunder. As of December 31, 2016, the Company is in compliance with the Loan Agreement covenants. In connection with the Loan Agreement, the Company incurred $8.2 million of costs (including interest on amounts held in the escrow account between September 30, 2016 and November 15, 2016). Furthermore, an incremental $4 million will become payable when principal of the Term Loan is repaid. As part of the Company's entry into the Loan Agreement, the Company issued the Warrant with a fair market value of $5.8 million . The fair value of the Warrant, as well as costs related to the Term Loan issuance, are recorded as deductions to the Term Loan balance on the Balance Sheet. These amounts are being amortized using the effective interest method over the life of the related Term Loan. The $4 million that will be paid when principal is repaid is being accreted to the Term Loan balance each quarter on a per diem basis.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions On October 13, 2016, in connection with the Rights Offering as discussed above, the Company entered into an investment agreement or "Backstop Agreement," with M&F, and other backstop parties (the "Backstop Parties"). Under the term of the Backstop Agreement, the Backstop Parties agreed to purchase, pursuant to a separate private placement, a number of shares of common stock equal to the numbers of shares that would have not been subscribed for in the Rights Offering. Under the Backstop Agreement, the subscription price was set to be equal to the subscription price applicable to all shareholders under the Rights Offering. The Rights Offering was fully subscribed, the Backstop Parties were not required to draw on such commitment. When shares were issued to the Backstop Parties in payment of the backstop fee, the stock price of SIGA common stock was $2.49 per share (the closing price of the Company’s common stock on November 16, 2016). The fair value of the shares issued in satisfaction of the backstop fee has been expensed on the income statement in 2016. There are no remaining payment obligations to the Backstop Parties under the Backstop Agreement. In October 2012, the Company funded a letter of credit and deposit to take advantage of a lease for office space secured by an affiliate of M&F from a third party landlord on behalf of the Company. Pursuant to such letter of credit, in January 2013 the Company entered into a sublease in which the Company will pay all costs associated with the lease, including rent. All payments made by the Company pursuant to the sublease will either be directly or indirectly made to the third-party landlord and not retained by M&F or any affiliate. The new sublease replaced a prior Office Services Agreement, and occupancy commenced on April 1, 2013. The sublease allowed for a free rent period of five months beginning April 1, 2013; subsequent to the free rent period, monthly rent payments are $60,000 for the first five years and $63,000 for the next two years. Upon expiration on September 1, 2020, the sublease and lease provides for two consecutive five year renewal options. A member of the Company’s Board of Directors is a member of the Company’s outside counsel. During the years ended December 31, 2016 , 2015 and 2014 , the Company incurred costs of $ 1.5 million, $602,000 and $822,000 , respectively, related to services provided by the outside counsel. On December 31, 2016 , the Company’s outstanding payables included $93,573 payable to the outside counsel.

Inventory

Inventory	12 Months Ended
	Dec. 31, 2016
Inventory Disclosure [Abstract]
Inventory	Inventory Due to the deferral of revenue under the BARDA Contract (see Note 3 to the financial statement for additional information), amounts that would be otherwise recorded as cost of goods sold for delivered courses are recorded as deferred costs on the balance sheet. The value of inventory represents the costs incurred to manufacture TPOXX® under the BARDA Contract. Additional costs incurred to complete production of courses of TPOXX® will be recorded as inventory and reclassified to deferred costs upon delivery to the extent related revenue is deferred. Inventory consisted of the following at December 31, 2016 and 2015 : 2016 2015 Work in-process $ 18,916,084 $ 12,447,088 Finished goods 7,293,880 — Inventory $ 26,209,964 $ 12,447,088 For the year ended December 31, 2015, research and development expense included inventory write-downs of approximately $60,000 .

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment consisted of the following at December 31, 2016 and 2015 : 2016 2015 Leasehold improvements $ 2,542,044 $ 2,542,044 Computer equipment 770,479 754,502 Furniture and fixtures 455,220 452,696 3,767,743 3,749,242 Less - accumulated depreciation (3,468,266 ) (3,299,417 ) Property, plant and equipment, net $ 299,477 $ 449,825 Depreciation and amortization expense on property, plant, and equipment was $174,275 , $247,357 , and $351,561 for the years ended December 31, 2016 , 2015 , and 2014 , respectively.

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2016
Payables and Accruals [Abstract]
Accrued Expenses	Accrued Expenses Accrued expenses and other current liabilities consisted of the following at December 31, 2016 and 2015 : 2016 2015 Bonus $ 2,357,194 $ 580,801 Professional fees 481,641 597,721 Vacation 262,664 227,863 Other (primarily R&D vendors and CMOs) 1,483,253 1,982,223 Accrued expenses and other current liabilities $ 4,584,752 $ 3,388,608

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes At December 31, 2016 , 2015 and 2014 the Company's provision benefit for income taxes is comprised of the following: 2016 2015 2014 Current: Federal $ (5,093 ) $ 439,934 $ (10,428 ) State and local (1,446 ) 946 (30,375 ) Total current provision (benefit) (6,539 ) 440,880 (40,803 ) Deferred: Federal 21,252 19,006 53,198,632 State and local (829 ) 2,097 370,439 Total deferred provision 20,423 21,103 53,569,071 Total provision $ 13,884 $ 461,983 $ 53,528,268 At December 31, 2016 and 2015 , the Company’s deferred tax assets and liabilities are comprised of the following: 2016 2015 Deferred income tax assets: Net operating losses $ 72,726,440 $ 22,701,028 Deferred research and development costs 669,602 1,130,413 Amortization of intangible assets 665,531 887,906 Share-based compensation 1,687,243 1,947,019 Fixed assets 667,008 662,011 Deferred revenue 102,520,433 59,892,477 Alternative minimum tax credits 2,029,190 2,034,283 Loss contingency — 73,421,980 Other 1,337,941 — Deferred income tax assets 182,303,388 162,677,117 Less: valuation allowance (155,465,173 ) (143,522,669 ) Deferred income tax assets, net of valuation allowance $ 26,838,215 $ 19,154,448 Deferred income tax liabilities: Amortization of goodwill (287,729 ) (267,598 ) Capitalized contract costs (25,854,435 ) (18,922,571 ) Other (982,117 ) (229,922 ) Deferred income tax liability, net $ (286,066 ) $ (265,643 ) The recognition of a valuation allowance for deferred taxes requires management to make estimates and judgments about the Company’s future profitability which are inherently uncertain. The Company assesses all available positive and negative evidence to determine if its existing deferred tax assets are realizable on a more-likely-than-not basis. In making such assessment, the Company considered the reversal of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operating results. The ultimate realization of a deferred tax asset is ultimately dependent on the Company's generation of sufficient taxable income within the available net operating loss carryback and/or carryforward periods to utilize the deductible temporary differences. Based on the weight of available evidence including three-year cumulative pre-tax losses, the Company continued to conclude that its deferred tax assets are not realizable on a more-likely-than-not basis and that a full valuation allowance is required. The valuation allowance increased by $11.9 million from prior year related primarily to current year operating losses for which no tax benefit was provided. The Company may amortize indefinite-lived intangible assets for tax purposes which are not amortizable for financial reporting purposes. The deferred tax liability at December 31, 2016 and December 31, 2015 relates to the tax effect of differences between financial reporting and tax bases of intangible assets that are not expected to reverse within the Company's net operating loss carryforward period. As of December 31, 2016 , the Company had $204.9 million of federal net operating loss carryforwards, which expire in 2023 to 2036, to offset future taxable income. In addition, approximately $1.6 million of federal net operating loss carryforwards are attributable to excess tax deductions on share-based compensation activity which will be realized as a benefit to Additional Paid-in Capital when such deductions reduce income taxes payable. As of December 31, 2016, the Company has approximately $2.0 million of alternative minimum tax credit which will be carried forward indefinitely. The Company’s effective tax rate differs from the U.S. Federal Statutory income tax rate of 35% as follows: 2016 2015 2014 Statutory federal income tax rate (35.0 )% (35.0 )% (35.0 )% State tax benefit 0.6 % — % 0.2 % Gain (loss) from fair value of common warrants 0.8 % — % — % Reorganization costs 3.3 % 7.0 % 0.4 % Other 0.2 % 1.4 % — % Valuation allowance on deferred tax assets 30.1 % 27.8 % 59.7 % Effective tax rate — % 1.2 % 25.3 % For the year ended December 31, 2016 and December 31, 2015, the Company’s effective tax rate differs from the statutory rate principally due to operating losses for which no tax benefit was provided and nondeductible reorganization expenses. For the year ended December 31, 2014 the Company's effective tax rate differs from the statutory rate principally due to the Company's conclusion that they could no longer realize its deferred tax assets on a more-likely-than-not basis.. The Company applies the applicable authoritative guidance which prescribes a comprehensive model for the manner in which a company should recognize, measure, present and disclose in its financial statements all material uncertain tax positions that the Company has taken or expects to take on a tax return. As of December 31, 2016 and 2015, the Company has no uncertain tax positions. There are no uncertain tax positions for which it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase or decrease within twelve months from December 31, 2016. The Company files federal income tax returns and income tax returns in various state and local tax jurisdictions. The open tax years for U.S. federal, state and local tax returns is 2013 - 2016; open tax years relating to any of the company’s net operating losses begin in 1998. In the event that the Company concludes that it is subject to interest and/or penalties arising from uncertain tax positions, the Company will present interest and penalties as a component of income taxes. No amounts of interest or penalties were recognized in the Company’s consolidated financial statements for each of the years in the three-year period ended December 31, 2016.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Operating lease commitments The Company leases its Corvallis, Oregon, facilities and office space under an operating lease, most recently amended in April 2015, which expires in 2017. Pursuant to an order entered by the Bankruptcy Court in April 2015, the Company assumed the Corvallis Lease with Research Way Investments, as amended by the Tenth Addendum to Commercial Lease, for the Company's research and development facility. In connection with the Tenth Addendum to the Commercial Lease, the Company relinquished the second floor space at its research and development facility, which reduces the rent expense to approximately $35,000 per month, starting May 1, 2015. In January 2013, we entered into a sublease with an affiliate of M&F for corporate office space in New York City under an operating lease which commenced in April 2013 and expires in 2020 (see Note 8 for further description of the lease arrangement). The respective leases contain annual escalation clauses, renewal provisions and generally require us to pay utilities, insurance, taxes and other operating expenses. Rental expense, including charges for maintenance, utilities, real estate taxes and other operating expenses, totaled $1.2 million , $1.4 million and $1.6 million for the years ended December 31, 2016 , 2015 and 2014 , respectively. Future minimum cash rental commitments under non-cancelable operating leases as of December 31, 2016 are expected to be in the future as follows: 2017 1,242,797 2018 739,772 2019 766,476 2020 512,788 Total $ 3,261,833 Legal Proceedings After several years of proceedings in litigation initiated by PharmAthene in 2006, the Delaware Court of Chancery on August 8, 2014 issued an opinion and order in which it determined, among other things, that PharmAthene was entitled to a lump sum damages award for its lost profits including interest and fees, based on SIGA’s contract with BARDA for the purchase of 2 million courses of TPOXX® which was allegedly anticipated as of December 2006. On September 16, 2014, as a consequence of SIGA’s chapter 11 filing, the legal proceedings with PharmAthene were stayed (see Note 1 to the financial statements), except that the parties agreed by stipulation approved by the Court on October 8, 2014 that the litigation could proceed. On January 15, 2015, the Delaware Court of Chancery entered its Final Order and Judgment (the "Final Order and Judgment") awarding PharmAthene approximately $195 million , including pre-judgment interest up to January 15, 2015 (the “Outstanding Judgment”). On December 23, 2015 the Delaware Supreme Court affirmed the Outstanding Judgment (the “Delaware Supreme Court Affirmation”). Pursuant to the Final Order and Judgment, SIGA also was liable to PharmAthene for $30,663.89 per day in post-judgment interest. On a series of dates up to and including a final payment on November 16, 2016, the Company paid PharmAthene an aggregate of $217 million to fully satisfy the Outstanding Judgment, including post-judgment interest, in accordance with the Plan as described in Note 1 to the financial statements. From time to time, we may be involved in a variety of claims, suits, investigations and proceedings arising from the ordinary course of our business, collections claims, breach of contract claims, labor and employment claims, tax and other matters. Although such claims, suits, investigations and proceedings are inherently uncertain and their results cannot be predicted with certainty, we believe that the resolution of such current pending matters, if any, will not have a material adverse effect on our business, consolidated financial position, results of operations or cash flow. Regardless of the outcome, litigation can have an adverse impact on us because of legal costs, diversion of management resources and other factors.

Financial Information By Quarte

Financial Information By Quarter (Unaudited)	12 Months Ended
	Dec. 31, 2016
Quarterly Financial Information [Abstract]
Financial Information By Quarter	Financial Information By Quarter (Unaudited) Three Months Ended 2016 March 31 June 30 September 30 December 31 (in thousands, except for per share data) Revenues 1,270 1,901 4,658 7,159 Selling, general and administrative 2,656 3,739 2,855 4,464 Research and development 2,536 2,948 6,069 8,158 Patent preparation fees 220 240 230 219 Interest on PharmAthene liability 2,917 4,259 3,566 927 Operating loss (7,059 ) (9,285 ) (8,062 ) (6,609 ) Net loss (10,449 ) (9,566 ) (9,244 ) (10,439 ) Earnings (loss) per share: basic and diluted (0.19 ) (0.18 ) (0.17 ) (0.15 ) Three Months Ended 2015 March 31 June 30 September 30 December 31 (in thousands, except for per share data) Revenues $ 1,192 $ 1,468 $ 1,327 $ 4,189 Selling, general and administrative 3,088 2,605 2,321 2,568 Research and development 2,811 2,959 2,427 4,934 Patent preparation fees 333 236 194 246 Litigation accrual expense — — 14 14,393 Operating loss (5,040 ) (4,332 ) (3,629 ) (17,952 ) Net loss (7,153 ) (6,573 ) (5,631 ) (20,094 ) Earnings (loss) per share: basic and diluted $ (0.13 ) $ (0.12 ) $ (0.10 ) $ (0.38 )

Summary of Significant Accoun21

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The consolidated financial statements and related disclosures are prepared in conformity with accounting principles generally accepted in the United States of America. Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and revenue and expenses during the period reported. The most significant estimates include the variables used in the calculation of fair value of stock-based awards including options and warrants granted or issued by the Company; reported amounts of revenue; calculation of contingencies; and the realization of deferred tax assets. Estimates and assumptions are reviewed periodically and the effects of revisions are reflected in the financial statements in the period they are determined to be necessary. Actual results could differ from these estimates.
Basis of Presentation	Basis of presentation The consolidated financial statements are presented in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) and reflect the consolidated financial position, results of operations and cash flows for all periods presented.
Cash Equivalents	Cash Equivalents The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents.
Restricted Cash and Cash Equivalents	Restricted Cash and Cash Equivalents A portion of the Company’s cash received under the Loan Agreement is restricted. In accordance with the Loan Agreement, cash placed in the reserve account is restricted. Except for $5 million , cash in the reserve account can only be utilized to pay interest on the Term Loan. The aforementioned $5 million in the reserve account can be withdrawn after June 30, 2018 upon the satisfaction of certain conditions. As of December 31, 2016, the restricted cash balance was $27.5 million of which $10.1 million is designated as a current asset and the remainder is designated as non-current. See Note 7 to the financial statements for additional information.
Concentration of Credit Risk	Concentration of Credit Risk The Company has cash in bank accounts that exceed the Federal Deposit Insurance Corporation insured limits. The Company has not experienced any losses on its cash accounts and no allowance has been provided for potential credit losses because management believes that any such losses would be minimal, if any.
Accounts Receivable	Accounts Receivable Accounts receivable are recorded net of provisions for doubtful accounts. At December 31, 2016 and 2015 , 100% of accounts receivables represented receivables from Biomedical Advanced Research and Development Authority (“BARDA”) and National Institutes of Health (“NIH”). An allowance for doubtful accounts is based on specific analysis of the receivables. At December 31, 2016 and 2015 , the Company had no allowance for doubtful accounts.
Inventory	Inventory Inventories are stated at the lower of cost or estimated realizable value. The Company capitalizes inventory costs associated with the Company’s products when, based on management’s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed as research and development. Inventory is evaluated for impairment periodically to identify inventory that may expire prior to expected sale or has a cost basis in excess of its estimated realizable value. If certain batches or units of product no longer meet quality specifications or become obsolete due to expiration, the Company records a charge to write down such unmarketable inventory to its estimated realizable value.
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment are stated at cost, net of accumulated depreciation. Depreciation is provided on a straight-line method over the estimated useful lives of the various asset classes. The estimated useful lives are as follows: 5 years for laboratory equipment; 3 years for computer equipment; and 7 years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the estimated useful lives of the assets or the lease term. Maintenance, repairs and minor replacements are charged to expense as incurred.
Warrant Liability	Warrant Liability The Company accounts for warrants in accordance with the authoritative guidance which requires that free-standing derivative financial instruments with certain anti-dilution features be classified as assets or liabilities at the time of the transaction, and recorded at their fair value. Fair value is estimated using model-derived valuations. Any changes in the fair value of the derivative instruments are reported in earnings or loss as long as the derivative contracts are classified as assets or liabilities.
Revenue Recognition	Revenue Recognition Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed or determinable, collectability is reasonably assured, title and risk of loss have been transferred to the customer and there are no further contractual obligations. Certain arrangements may provide for multiple deliverables, in which there may be a combination of: up-front licenses; research, development, regulatory or other services; and delivery of product. Multiple deliverable arrangements can be divided into separate units of accounting if the deliverables in the arrangement meet the following criteria: (i) the delivered item(s) have value to the customer on a standalone basis and (ii) in circumstances in which an arrangement includes a general right of return with respect to delivered items, then performance of the remaining deliverables must be considered probable and substantially in control of the Company. If multiple deliverables cannot be divided into separate units of accounting then the deliverables must be combined into a single unit of accounting. Total consideration in a multiple deliverable arrangement is allocated to units of accounting on a relative fair value of selling price basis. Consideration allocated to a delivered item or unit of accounting is limited to the amount that is not contingent upon delivery of additional items. Direct costs incurred by the Company and associated with the deferral of revenue for a unit of accounting will also be deferred and will be recognized as expenses over the same period that the related deferred revenue is recognized as revenue. Subject to the above, payments for development activities are recognized as revenue when earned, over the period of effort. Funding for the acquisition of capital assets under cost-plus-fee contracts or grants is evaluated for appropriate recognition as a reduction to the cost of the asset, a financing arrangement, or revenue based on the specific terms of the related grant or contract. For the years ended December 31, 2016 , 2015 , and 2014 , revenues from BARDA and NIH were 100% of total revenues recognized by the Company.
Research and Development	Research and Development Research and development expenses include costs directly and indirectly attributable to the conduct of research and development programs, and performance of the BARDA Contract, including employee related costs, materials, supplies, depreciation on and maintenance of research equipment, the cost of services provided by outside contractors, including services related to the Company’s clinical trials and facility costs, such as rent, utilities, and general support services. All costs associated with research and development are expensed as incurred. Costs related to the acquisition of technology rights, for which development work is still in process, and that have no alternative future uses, are expensed as incurred.
Goodwill	Goodwill The Company evaluates goodwill for impairment at least annually or as circumstances warrant. The impairment review process compares the fair value of the reporting unit in which goodwill resides to its carrying value. The Company operates as one business and one reporting unit. Therefore, the goodwill impairment analysis is performed on the basis of the Company as a whole, using the market capitalization of the Company as an estimate of its fair value.
Share-based Compensation	Share-based Compensation Stock-based compensation expense for all share-based payment awards made to employees and directors is determined on the grant date; for options awards, fair value was estimated using the Black-Scholes model and for stock appreciation rights (“SARs”), fair value was estimated using the Monte Carlo method. The value of the portion of the award that is ultimately expected to vest is recorded as expense over the requisite service periods in the Company’s consolidated statement of operations. These compensation costs are recognized net of an estimated forfeiture rate over the requisite service periods of the awards. Forfeitures are estimated on the date of the respective grant and revised if actual or expected forfeiture activity differs from original estimates.
Income Taxes	Income Taxes The Company recognizes income taxes utilizing the asset and liability method of accounting for income taxes. Under this method, deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities at enacted tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is established if it is more likely than not that some or the entire deferred tax asset will not be realized. The recognition of a valuation allowance for deferred taxes requires management to make estimates and judgments about the Company’s future profitability which are inherently uncertain.
Net Loss per Share	Net Loss per Share The objective of basic earnings per share (“EPS”) is to measure the performance of an entity over the reporting period by dividing income (loss) by the weighted average shares outstanding. The objective of diluted EPS is consistent with that of basic EPS, except that it also gives effect to all potentially dilutive common shares outstanding during the period.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying value of cash and cash equivalents, restricted cash and cash equivalents, accounts payable and accrued expenses approximates fair value due to the relatively short maturity of these instruments. Common stock warrants which are classified as liabilities are recorded at their fair market value as of each reporting period. The measurement of fair value requires the use of techniques based on observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our market assumptions. The inputs create the following fair value hierarchy: • Level 1 – Quoted prices for identical instruments in active markets. • Level 2 – Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations where inputs are observable or where significant value drivers are observable. • Level 3 – Instruments where significant value drivers are unobservable to third parties. The Company uses model-derived valuations where certain inputs are unobservable to third parties to determine the fair value of certain common stock warrants on a recurring basis and classify such liability classified warrants in Level 3. On September 2, 2016, the date of issuance of the current liability classified warrant, the Company used a Monte Carlo simulation model to calculate the fair market value of the warrant.The Company compared the Monte Carlo simulation model calculation to a Black-Scholes model calculation. These models generated substantially equal values. As such, the Company utilized a Black-Scholes model for December 31, 2016, consisting of the following variables: (i) the closing price of SIGA’s common stock; (ii) the expected remaining life of the liability classified warrant; (iii) the expected volatility using a weighted-average of historical volatilities from a combination of SIGA and comparable companies; and (iv) the risk-free market rate. At December 31, 2016, the fair value of liability classified warrant is $6.7 million At December 31, 2016, the fair value of the debt was $69.9 million and the carrying value of the debt was $66.6 million . The Company used a discounted cash flow model to estimate the fair value of the debt by applying a discount rate to future payments expected to be made as set forth in the Loan Agreement. The fair value of the loan was measured using level 3 inputs. The discount rate was determined using market participant assumptions. This valuation required significant judgment. There were no transfers between levels of the fair value hierarchy during 2016.
Legal Contingencies	Legal Contingencies The Company is subject to certain contingencies arising in the ordinary course of business. The Company records accruals for these contingencies to the extent that a loss is both probable and reasonably estimable. If some amount within a range of loss appears to be a better estimate than any other amount within the range, that amount is accrued. Alternatively, when no amount within a range of loss appears to be a better estimate than any other amount, the lowest amount in the range is accrued. The Company expenses legal costs associated with loss contingencies as incurred. We record anticipated recoveries under existing insurance contracts when recovery is assured.
Segment Reporting	Segment Information The Company is managed and operated as one business. The entire business is managed by a single management team that reports to the chief executive officer. The Company does not operate separate lines of business or separate business entities with respect to any of its product candidates. Accordingly, the Company does not prepare discrete financial information with respect to separate product areas or by location and only has one reportable segment.
Recent Accounting Pronouncements	Recent Accounting Pronouncements On November 17, 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, a consensus of the FASB’s Emerging Issues Task Force. The new standard requires that the statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Entities will also be required to reconcile such total to amounts on the balance sheet and disclose the nature of the restrictions. The standard is effective for financial statements issued for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The guidance requires application using a retrospective transition method. The Company is currently evaluating the impact that ASU 2016-18 will have on its consolidated financial statements. On August 26, 2016, the FASB issued ASU 2016­ -15, Statement of Cash Flows (Topic 230), a consensus of the FASB’s Emerging Issues Task Force. The new guidance is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. The standard is effective for financial statements issued for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted, provided that all of the amendments are adopted in the same period. The guidance requires application using a retrospective transition method. The Company is currently evaluating the impact that ASU 2016-15 will have on its consolidated financial statements. In March 2016, the FASB amended the existing accounting standards for stock-based compensation, ASU 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. The amendments impact several aspects of accounting for share-based payment transactions, including the income tax consequences, forfeitures, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The Company is required to adopt the amendments in the first quarter of 2017, with early adoption permitted. If early adoption is elected, all amendments must be adopted in the same period. The manner of application varies by the various provisions of the guidance, with certain provisions applied on a retrospective or modified retrospective approach, while others are applied prospectively. The Company assessed the impact of ASU 2016-09 and believes adoption of the ASU will not have a material impact on its consolidated financial statements. On February 25, 2016, the FASB issued ASU 2016-02 Leases, which relates to the accounting of leasing transactions. This standard requires a lessee to record on the balance sheet the assets and liabilities for the rights and obligations created by leases with lease terms of more than 12 months. In addition, this standard requires both lessees and lessors to disclose certain key information about lease transactions. This standard will be effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact that ASU 2016-02 will have on its consolidated financial statements. In August 2014, the FASB issued Accounting Standard Update ( “ ASU ” ) No. 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40) Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern . This ASU requires management to assess whether there is substantial doubt about the entity’s ability to continue as a going concern and, if so, disclose that fact. Management will also be required to evaluate and disclose whether its plans alleviate that doubt. This ASU states that, when making this assessment, management should consider relevant conditions or events that are known or reasonably knowable on the date the financial statements are issued or available to be issued. This ASU is effective for annual periods ending after December 15, 2016 and interim periods thereafter, and early adoption is permitted. The Company adopted ASU 2014-15 and for adoption impact see Note 1 to the financial statements under "liquidity". In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) . ASU No. 2014-09 supersedes the revenue recognition requirements in Topic 605, Revenue Recognition , and most industry-specific revenue recognition guidance throughout the Industry Topics of the Accounting Standards Codification. Additionally, this update supersedes some cost guidance included in Subtopic 605-35, Revenue Recognition-Construction-Type and Production-Type Contracts . The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. It is effective for the first interim period within annual reporting periods beginning after December 15, 2017, and early adoption is permitted for the first interim periods beginning after December 15, 2016. The Company is assessing the potential impact of the variable consideration related to milestones and other payments received as well as the impact of the potential replacement obligation for courses already delivered to BARDA. The Company will continue to assess the impact of ASU 2014-09.

Summary of Significant Accoun22

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The Company incurred losses for the years ended December 31, 2016 , 2015 and 2014 . For all periods presented, all equity instruments are excluded from the calculation of diluted earnings (loss) per share as the effect of such shares is anti-dilutive. The weighted average number of equity instruments excluded consist of: Year Ended December 31, 2016 2015 2014 Stock Options 1,789,751 2,047,083 2,179,643 Stock-Settled Stock Appreciation Rights 360,031 368,331 388,325 Restricted Stock Units 705,850 700,265 1,206,534 Warrants 877,303 82,192 772,903
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	The following table presents changes in the liability classified warrant measured at fair value using Level 3 inputs: Fair Value Measurements of Level 3 liability classified warrant Warrant liability at September 02, 2016 - issuance date $ 5,832,624 Increase in fair value of warrant liability 894,785 Warrant liability at December 31, 2016 $ 6,727,409

Liabilities Subject to Compro23

Liabilities Subject to Compromise (Tables)	12 Months Ended
	Dec. 31, 2016
Liabilities Subject to Compromise [Abstract]
Liabilies subject to compromise	As of December 31, 2016 and 2015, Liabilities Subject to Compromise consisted of the following: December 31, 2016 December 31, 2015 Accounts payable - pre-petition $ — $ 834,219 Accrual- PharmAthene Litigation — 205,400,068 (1 ) Other accrued expenses - pre-petition — 737,883 Total $ — $ 206,972,170 (1) Includes a $3.2 million accrual at December 31, 2015 for reimbursement of PharmAthene attorney's fees and expert fees, against which there is a $2.7 million surety bond that has cash collaterization of $1.3 million . In 2016, the Company received the $1.2 million of cash collaterization from a surety bond upon satisfaction of the PharmAthene claim.
Reorganization items	As of December 31, 2016 and 2015, reorganization items consisted of the following: December 31, 2016 December 31, 2015 Legal fees $ 1,951,381 $ 5,719,052 Professional fees 1,732,521 2,027,827 Trustee fees 33,000 59,000 Other — 5,672 Total $ 3,716,902 $ 7,811,551

Stock Compensation Plans (Table

Stock Compensation Plans (Tables)	12 Months Ended
	Dec. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock options activity	A summary of the Company’s stock option activity is as follows: Number of Options Weighted Average Exercise Price Weighted Average Remaining Life (in years) Aggregate Intrinsic Value (in thousands) Outstanding at January 1, 2016 1,924,967 $ 4.51 Granted — — Exercised — — Canceled/Expired (215,000 ) 2.47 Outstanding at December 31, 2016 1,709,967 $ 4.76 1.96 $ — Vested and expected to vest at December 31, 2016 1,709,967 $ 4.76 1.96 $ — Exercisable at December 31, 2016 1,709,967 $ 4.76 1.96 $ —
Stock appreciation rights award activity	A summary of the Company’s SSAR activity is as follows: Number of SSARs Weighted Average Exercise Price Weighted Average Remaining Life (in years) Aggregate Intrinsic Value (in thousands) Outstanding at January 1, 2016 1,209,274 $ 3.53 Granted — — Exercised — — Canceled/Expired (26,250 ) 3.53 Outstanding at December 31, 2016 1,183,024 $ 3.53 2.09 $ — Vested and expected to vest at December 31, 2016 1,183,024 $ 3.53 2.09 $ — Exercisable at December 31, 2016 1,183,024 $ 3.53 2.09 $ —
Restricted stock and restricted stock units activity	RSUs awarded to employees vest in equal annual installments over a three-year period and RSUs awarded to directors of the Company vest over a one-year period. A summary of the Company’s RSU activity is as follows: Number of RSUs Weighted Average Grant-Date Fair Value Outstanding at January 1, 2016 661,671 $ 2.96 Granted 1,302,353 2.24 Vested (483,335 ) 2.81 Canceled/Expired (25,000 ) 3.35 Outstanding at December 31, 2016 1,455,689 $ 2.36

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2016
Inventory Disclosure [Abstract]
Inventory	Inventory consisted of the following at December 31, 2016 and 2015 : 2016 2015 Work in-process $ 18,916,084 $ 12,447,088 Finished goods 7,293,880 — Inventory $ 26,209,964 $ 12,447,088

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Property, plant and equipment	Property, plant and equipment consisted of the following at December 31, 2016 and 2015 : 2016 2015 Leasehold improvements $ 2,542,044 $ 2,542,044 Computer equipment 770,479 754,502 Furniture and fixtures 455,220 452,696 3,767,743 3,749,242 Less - accumulated depreciation (3,468,266 ) (3,299,417 ) Property, plant and equipment, net $ 299,477 $ 449,825

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2016
Payables and Accruals [Abstract]
Accrued Expenses	Accrued expenses and other current liabilities consisted of the following at December 31, 2016 and 2015 : 2016 2015 Bonus $ 2,357,194 $ 580,801 Professional fees 481,641 597,721 Vacation 262,664 227,863 Other (primarily R&D vendors and CMOs) 1,483,253 1,982,223 Accrued expenses and other current liabilities $ 4,584,752 $ 3,388,608

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Schedule of components of income tax expense (benefit)	At December 31, 2016 , 2015 and 2014 the Company's provision benefit for income taxes is comprised of the following: 2016 2015 2014 Current: Federal $ (5,093 ) $ 439,934 $ (10,428 ) State and local (1,446 ) 946 (30,375 ) Total current provision (benefit) (6,539 ) 440,880 (40,803 ) Deferred: Federal 21,252 19,006 53,198,632 State and local (829 ) 2,097 370,439 Total deferred provision 20,423 21,103 53,569,071 Total provision $ 13,884 $ 461,983 $ 53,528,268
Schedule of deferred tax assets and liabilities	At December 31, 2016 and 2015 , the Company’s deferred tax assets and liabilities are comprised of the following: 2016 2015 Deferred income tax assets: Net operating losses $ 72,726,440 $ 22,701,028 Deferred research and development costs 669,602 1,130,413 Amortization of intangible assets 665,531 887,906 Share-based compensation 1,687,243 1,947,019 Fixed assets 667,008 662,011 Deferred revenue 102,520,433 59,892,477 Alternative minimum tax credits 2,029,190 2,034,283 Loss contingency — 73,421,980 Other 1,337,941 — Deferred income tax assets 182,303,388 162,677,117 Less: valuation allowance (155,465,173 ) (143,522,669 ) Deferred income tax assets, net of valuation allowance $ 26,838,215 $ 19,154,448 Deferred income tax liabilities: Amortization of goodwill (287,729 ) (267,598 ) Capitalized contract costs (25,854,435 ) (18,922,571 ) Other (982,117 ) (229,922 ) Deferred income tax liability, net $ (286,066 ) $ (265,643 )
Schedule of effective income tax rate reconciliation	The Company’s effective tax rate differs from the U.S. Federal Statutory income tax rate of 35% as follows: 2016 2015 2014 Statutory federal income tax rate (35.0 )% (35.0 )% (35.0 )% State tax benefit 0.6 % — % 0.2 % Gain (loss) from fair value of common warrants 0.8 % — % — % Reorganization costs 3.3 % 7.0 % 0.4 % Other 0.2 % 1.4 % — % Valuation allowance on deferred tax assets 30.1 % 27.8 % 59.7 % Effective tax rate — % 1.2 % 25.3 %

Commitments and Contingencies O

Commitments and Contingencies Operating Lease Commitments (Tables)	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases	Future minimum cash rental commitments under non-cancelable operating leases as of December 31, 2016 are expected to be in the future as follows: 2017 1,242,797 2018 739,772 2019 766,476 2020 512,788 Total $ 3,261,833

Financial Information By Quar30

Financial Information By Quarter (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2016
Quarterly Financial Information [Abstract]
Schedule of quarterly financial information	Financial Information By Quarter (Unaudited) Three Months Ended 2016 March 31 June 30 September 30 December 31 (in thousands, except for per share data) Revenues 1,270 1,901 4,658 7,159 Selling, general and administrative 2,656 3,739 2,855 4,464 Research and development 2,536 2,948 6,069 8,158 Patent preparation fees 220 240 230 219 Interest on PharmAthene liability 2,917 4,259 3,566 927 Operating loss (7,059 ) (9,285 ) (8,062 ) (6,609 ) Net loss (10,449 ) (9,566 ) (9,244 ) (10,439 ) Earnings (loss) per share: basic and diluted (0.19 ) (0.18 ) (0.17 ) (0.15 ) Three Months Ended 2015 March 31 June 30 September 30 December 31 (in thousands, except for per share data) Revenues $ 1,192 $ 1,468 $ 1,327 $ 4,189 Selling, general and administrative 3,088 2,605 2,321 2,568 Research and development 2,811 2,959 2,427 4,934 Patent preparation fees 333 236 194 246 Litigation accrual expense — — 14 14,393 Operating loss (5,040 ) (4,332 ) (3,629 ) (17,952 ) Net loss (7,153 ) (6,573 ) (5,631 ) (20,094 ) Earnings (loss) per share: basic and diluted $ (0.13 ) $ (0.12 ) $ (0.10 ) $ (0.38 )

Organization and Basis of Pre31

Organization and Basis of Presentation Plan of Reorganization (Details) - USD ($)	Dec. 22, 2016	Dec. 31, 2016	Oct. 19, 2016	Oct. 01, 2016	Sep. 30, 2016	Apr. 12, 2016
Organization and Basis of Presentation [Abstract]
Amount paid to settle claims		$ 800,000
Amount to be paid on effective date of plan of reorganization						$ 5,000,000
Payment to extend 120 days to satisfy pharmAthene claim		$ 20,000,000
Payment to extend days to satisfy claim			$ 100,000,000	$ 10,000,000	$ 100,000,000
Payments for legal settlements	$ 217,000,000

Organization and Basis of Pre32

Organization and Basis of Presentation Liquidity (Details) course in Millions, $ in Millions	May 13, 2011USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2016USD ($)course	Feb. 28, 2017USD ($)
Procurement Contract [Line Items]
Reduced holdback amount	$ 41		$ 41
BARDA Contract
Procurement Contract [Line Items]
Proceeds from manufacture and physical delivery of course, government contractses			$ 360.4
Government contract, total number of courses required to be delivered | course			2
Reduced holdback amount			$ 41
Subsequent Event | BARDA Contract
Procurement Contract [Line Items]
Proceeds from manufacture and physical delivery of course, government contractses				$ 8.5
Scenario, Forecast | BARDA Contract
Procurement Contract [Line Items]
Reduced holdback amount		$ 41

Organization and Basis of Pre33

Organization and Basis of Presentation Loan Agreement (Details) - Loan Agreement - USD ($)	12 Months Ended
	Dec. 31, 2016	Jun. 30, 2018	Sep. 02, 2016
Secured Debt
Debt Instrument [Line Items]
Line of credit facility	$ 80,000,000		$ 80,000,000
London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Margin for term loan	11.50%
Repayment of Interests | Secured Debt
Debt Instrument [Line Items]
Capacity available for specific purpose other than for trade purchases	$ 25,000,000
Payments Related to Litigation | Secured Debt
Debt Instrument [Line Items]
Capacity available for specific purpose other than for trade purchases	$ 50,000,000
Scenario, Forecast | Secured Debt
Debt Instrument [Line Items]
Additional borrowing capacity		$ 5,000,000

Organization and Basis of Pre34

Organization and Basis of Presentation Warrant (Details) - USD ($)	Sep. 02, 2016	Dec. 31, 2016	Dec. 31, 2015
Class of Warrant or Right [Line Items]
Exercise price of warrants	$ 2.29
Fair value of warrant		$ 6,727,409	$ 0
Warrants
Class of Warrant or Right [Line Items]
Warrants purchased, value	4,000,000
Exercise price of warrants	$ 1.50
Exercisable period for warrants (in years)	10 years
Warrants that can be purchased, shares	2,700,000
Warrants
Class of Warrant or Right [Line Items]
Fair value of warrant	$ 5,800,000	$ 6,700,000
Subscription Right | Warrants
Class of Warrant or Right [Line Items]
Exercise price of warrants	$ 1.50

Organization and Basis of Pre35

Organization and Basis of Presentation Rights Offering (Details) - USD ($)	Nov. 16, 2016	Dec. 31, 2016	Sep. 02, 2016
Class of Warrant or Right [Line Items]
Exercise price of warrants			$ 2.29
Equity Rights
Class of Warrant or Right [Line Items]
Equity offering	$ 35,300,000
Number of subscription rights called by each equity right	1
Common Stock | Subscription Right
Class of Warrant or Right [Line Items]
Amount to be invested by each right to purchase securities (in dollars per share)	$ 0.65
Exercise price of warrants	$ 1.50
Volume of weighted average price during market hours (as a percent)	85.00%
Private Placement
Class of Warrant or Right [Line Items]
Backstop fee		$ (1,764,240)
Share price	$ 2.49
Common Stock
Class of Warrant or Right [Line Items]
Issuance of common stock associated with rights offering, shares	23,523,195	23,523,195

Summary of Significant Accoun36

Summary of Significant Accounting Policies (Restricted Cash and Cash Equivalents) (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2016	Dec. 31, 2015
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash and cash equivalents		$ 27,500,000
Restricted cash and cash equivalents-short term		$ 10,138,890	$ 0
Secured Debt | Scenario, Forecast | Loan Agreement
Restricted Cash and Cash Equivalents Items [Line Items]
Additional borrowing capacity	$ 5,000,000

Summary of Significant Accoun37

Summary of Significant Accounting Policies (Accounts Receivable, Property, Plant and Equipment, and Net Loss Per Share) (Details)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Receivables percentage	100.00%	100.00%
Lab equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	5 years
Computer Equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	3 years
Furniture and Fixtures
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	7 years

Summary of Significant Accoun38

Summary of Significant Accounting Policies (Revenue) (Details)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Revenue, percentage	100.00%	100.00%	100.00%

Summary of Significant Accoun39

Summary of Significant Accounting Policies (Anti-dilutive Securities Exluded from Calculation of Diluted Loss per Share) (Details) - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive employee share-based awards, excluded	1,789,751	2,047,083	2,179,643
Stock Appreciation Rights (SARs)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive employee share-based awards, excluded	360,031	368,331	388,325
Restricted Stock Units (RSUs)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive employee share-based awards, excluded	705,850	700,265	1,206,534
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive employee share-based awards, excluded	877,303	82,192	772,903

Summary of Significant Accoun40

Summary of Significant Accounting Policies (Fair Value of Financial Instruments) (Details) - USD ($)	Dec. 31, 2016	Sep. 02, 2016	Dec. 31, 2015
Class of Warrant or Right [Line Items]
Fair value of warrant	$ 6,727,409		$ 0
Warrants
Class of Warrant or Right [Line Items]
Fair value of warrant	6,700,000	$ 5,800,000
Senior Secured Term Loan
Class of Warrant or Right [Line Items]
Loan outstanding	66,600,000
Senior Secured Term Loan | Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 2
Class of Warrant or Right [Line Items]
Loan outstanding	$ 69,900,000

Summary of Significant Accoun41

Summary of Significant Accounting Policies (Change in Level 3 Liability) (Details) $ in Thousands	4 Months Ended
	Dec. 31, 2016USD ($)
Accounting Policies [Abstract]
Warrant liability at September 02, 2016 - issuance date	$ 5,832,624
Increase in fair value of warrant liability	894,785
Warrant liability at December 31, 2016	$ 6,727,409

Procurement Contract and Rese42

Procurement Contract and Research Agreements (Details)	Jun. 24, 2011course	May 13, 2011USD ($)course	Dec. 31, 2016USD ($)coursecontractgrant	Dec. 31, 2015USD ($)course	Dec. 31, 2013USD ($)	Dec. 31, 2012USD ($)	Dec. 31, 2011USD ($)	Feb. 28, 2017USD ($)	Jul. 31, 2016USD ($)	Jun. 28, 2016USD ($)
Procurement Contract [Line Items]
Reduced holdback amount		$ 41,000,000	$ 41,000,000
Holdback amount pending FDA approval		102,500,000
Number of courses of TPOXX to be delivered to the government | course			467,000
Contract value of various options		122,700,000
Amount of option to be received from BARDA for approval for extension of 84 moth expiry		50,000,000
Contract value, detail of option exercisable, development activities		58,300,000
Contract value, detail of option exercisable, production activities		14,400,000
Contract value, option, FDA approval		$ 50,000,000
Deferred costs			$ 72,649,277	$ 52,936,428
Research and development revenue long-term contract			$ 13,200,000
Number of active contracts | contract			1
Number of active grants | grant			1
BARDA Contract
Procurement Contract [Line Items]
Number of courses to be delivered | course		2,000,000	2,000,000
Value of contract		$ 472,000,000
Contract value of manufacturing and delivery activities		$ 409,800,000	$ 41,000,000
Number of courses under modified contract | course	1,700,000	1,700,000
Contract value of development and support activities		$ 62,000,000
Government contract, number of free courses | course		300,000
Government contract, total number of courses required to be delivered | course			2,000,000
Reduced holdback amount			$ 41,000,000
Increase in payments for delivery of courses of TPOXX									$ 32,600,000	$ 61,500,000
Milestone payment			20,500,000		$ 8,200,000	$ 12,300,000
Proceeds from manufacture and physical delivery of course, government contractses			360,400,000
Proceeds from advance payments under the BARDA contract							$ 41,000,000
Proceeds from physical delivery of courses, government contracts					$ 278,400,000
Future proceeds to be received from BARDA			49,400,000
Future proceeds to be received from the future deliveries of courses to the government			8,500,000
Number of courses delivered and accepted at provisional dosage, once daily | course				1,300,000
Deferred costs			72,200,000	$ 52,500,000
Deferred revenue			$ 367,400,000
Subsequent Event | BARDA Contract
Procurement Contract [Line Items]
Proceeds from manufacture and physical delivery of course, government contractses								$ 8,500,000

Liabilities Subject to Compro43

Liabilities Subject to Compromise - Narrative (Details) - USD ($) $ in Thousands	Apr. 12, 2016	Dec. 31, 2016	Dec. 31, 2015
Liabilities Subject to Compromise [Abstract]
Legal and expert fees accrual - PharmAthene Litigation			$ 3,200
Surety bond		$ 2,700
Payment to post collateral for surety bond		1,200	1,300
Expense directly attributable to the implementation of the plan	$ 684
Reorganization payments		$ 4,600	$ 6,700

Liabilities Subject to Compro44

Liabilities Subject to Compromise (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Liabilities Subject to Compromise [Abstract]
Accounts payable - pre-petition	$ 0	$ 834,219
Accrual- PharmAthene Litigation	0	205,400,068
Other accrued expenses - pre-petition	0	737,883
Liabilities subject to compromise	$ 0	$ 206,972,170

Liabilities Subject to Compro45

Liabilities Subject to Compromise Reorganization items (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Reorganization [Abstract]
Legal fees	$ 1,951,381	$ 5,719,052
Professional fees	1,732,521	2,027,827
Trustee fees	33,000	59,000
Other	0	5,672
Total	$ 3,716,902	$ 7,811,551	$ 2,126,536

Stockholders' Equity - Narrativ

Stockholders' Equity - Narrative (Details) - USD ($)	Nov. 16, 2016	Oct. 13, 2016	Sep. 02, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Class of Warrant or Right [Line Items]
Capital units, authorized				620,000,000
Common stock, shares authorized				600,000,000	600,000,000
Preferred stock, shares authorized				20,000,000
Exercise price of warrants			$ 2.29
Fair value of warrant				$ 6,727,409	$ 0
Increase in fair value of warrant liability				$ 894,785	$ 0	$ (313,425)
Warrants
Class of Warrant or Right [Line Items]
Warrants that can be purchased, shares			2,700,000
Exercise price of warrants			$ 1.50
Warrants purchased, value			4,000,000
Exercisable period for warrants (in years)			10 years
Common Stock
Class of Warrant or Right [Line Items]
Issuance of common stock associated with rights offering, shares	23,523,195			23,523,195
Warrants
Class of Warrant or Right [Line Items]
Fair value of warrant			$ 5,800,000	$ 6,700,000
Risk free interest rate (as a percent)			1.60%	2.40%
Expected dividend rate (as a percent)			0.00%	0.00%
Expected term (in years)			10 years	9 years 8 months 1 day
Expected volatility rate (as a percent)			80.00%	80.00%
Increase in fair value of warrant liability				$ 895,000
Equity Rights
Class of Warrant or Right [Line Items]
Equity offering	$ 35,300,000
Warrants that can be purchased, shares	1
Subscription Right | Warrants
Class of Warrant or Right [Line Items]
Exercise price of warrants			$ 1.50
Common Stock | Subscription Right
Class of Warrant or Right [Line Items]
Amount to be invested by each right to purchase securities (in dollars per share)	$ 0.65
Exercise price of warrants	$ 1.50
Volume of weighted average price during market hours (as a percent)	85.00%
Private Placement
Class of Warrant or Right [Line Items]
Share price	$ 2.49
Backstop fee				$ (1,764,240)
Private Placement | Common Stock
Class of Warrant or Right [Line Items]
Stock Issued During Period, Shares, New Issues		708,530

Stock Compensation Plans - Narr

Stock Compensation Plans - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2012	Apr. 25, 2012	May 31, 2010
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized					4,500,000	2,000,000
Stock-based compensation expense	$ 775,541	$ 1,600,000	$ 2,400,000
Performance-based stock options		200,000
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation cost, net of estimated forfeitures	$ 4,000
Weighted average remaining requisite service period (in years)	6 months
Fair value of vested stock options	$ 0	$ 0	144,000
Total intrinsic value of stock options exercised	$ 0	$ 6,000	19,000
Performance-based stock options	200,000
Stock Appreciation Rights (SARs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares granted	0			1,400,000
Weighted average grant-date fair value, granted				$ 0.68
Award vesting period				3 years
Maximum number of shares to be issued	360,031	365,689
Fair value of vested stock appreciation rights	$ 0	$ 0	$ 267,000
Stock Appreciation Rights (SARs) | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period				7 years
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average remaining requisite service period (in years)	2 years 1 month 109 days
Number of shares granted	1,302,353
Weighted average grant-date fair value, granted	$ 2.24	$ 2	$ 3.23
Unrecognized stock-based compensation cost	$ 2,800,000
Fair value of stock compensation vested	$ 1,400,000	$ 1,800,000	$ 1,500,000
Restricted Stock Units (RSUs) | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	3 years
Restricted Stock Units (RSUs) | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period	1 year

Stock Compensation Plans (Stock

Stock Compensation Plans (Stock Plans and Stock Options) (Details) - Stock Options $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of shares outstanding at beginning of period | shares	1,924,967
Number of shares granted | shares	0
Number of shares exercised | shares	0
Number of shares canceled and expired | shares	(215,000)
Number of shares outstanding at end of period | shares	1,709,967
Number of shares vested and expected to vest | shares	1,709,967
Number of shares exercisable | shares	1,709,967
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Weighted average exercise price outstanding at beginning of period | $ / shares	$ 4.51
Weighted average exercise price, granted | $ / shares	0
Weighted average exercise price, exercised | $ / shares	0
Weighted average exercise price, canceled and expired | $ / shares	2.47
Weighted average exercise price outstanding at end of period | $ / shares	4.76
Weighted average exercise price, vested and expected to vest | $ / shares	4.76
Weighted average exercise price, exercisable | $ / shares	$ 4.76
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Weighted average remaining life, outstanding	1 year 350 days
Weighted average remaining life, vested and expected to vest	1 year 350 days
Weighted average remaining life, exercisable	1 year 350 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]
Intrinsic value, outstanding | $	$ 0
Intrinsic value, vested and expected to vest | $	0
Intrinsic value, exercisable | $	$ 0

Stock Compensation Plans (Sto49

Stock Compensation Plans (Stock Appreciation Rights) (Details) - Stock Appreciation Rights (SARs) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Number of shares outstanding at beginning of period	1,209,274
Number of shares granted	0	1,400,000
Number of shares exercised	0
Number of shares canceled and expired	(26,250)
Number of shares outstanding at end of period	1,183,024
Number of shares vested and expected to vest	1,183,024
Number of shares exercisable	1,183,024
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Exercise Price [Roll Forward]
Weighted average exercise price outstanding at beginning of period	$ 3.53
Weighted average exercise price granted	0
Weighted average exercise price exercised	0
Weighted average exercise price canceled and expired	3.53
Weighted average exercise price outstanding at end of period	3.53
Weighted average exercise price, vested and expected to vest	3.53
Weighted average exercise price, exercisable	$ 3.53
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]
Weighted average remaining life, outstanding	2 years 1 month 2 days
Weighted average remaining life, vested and expected to vest	2 years 1 month 2 days
Weighted average remaining life, exercisable	2 years 1 month 2 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]
Intrinsic value outstanding	$ 0
Intrinsic value, vested and expected to vest	$ 0
Intrinsic value, exercisable	$ 0

Stock Compensation Plans (Restr

Stock Compensation Plans (Restricted Stock Awards and Restricted Stock Units) (Details) - Restricted Stock Units (RSUs) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Number of shares outstanding at beginning of period	661,671
Number of shares granted	1,302,353
Number of shares vested	(483,335)
Number of shares canceled and expired	(25,000)
Number of shares outstanding at end of period	1,455,689	661,671
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Exercise Price [Roll Forward]
Weighted average grant-date fair value outstanding at beginning of period	$ 2.96
Weighted average grant-date fair value, granted	2.24	$ 2	$ 3.23
Weighted average grant-date fair value, vested	2.81
Weighted averaged grant-date fair value, canceled and expired	3.35
Weighted average grant-date fair value outstanding at end of period	$ 2.36	$ 2.96

Debt - Narrative (Details)

Debt - Narrative (Details) - USD ($)	Sep. 02, 2016	Dec. 31, 2017	Jun. 30, 2017	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2016	Jun. 30, 2018	Dec. 31, 2015
Debt Instrument [Line Items]
Fair value of warrant						$ 6,727,409		$ 0
London Interbank Offered Rate (LIBOR) | Loan Agreement
Debt Instrument [Line Items]
Margin for term loan						11.50%
Effective interest rate (as a percent)						18.30%
Warrants
Debt Instrument [Line Items]
Fair value of warrant	$ 5,800,000					$ 6,700,000
Secured Debt | Loan Agreement
Debt Instrument [Line Items]
Line of credit facility	80,000,000					80,000,000
Interest expense, debt						1,800,000
Interest paid on term loan						$ 1,200,000
Potential increase in interest rate						2.00%
Costs incurred	$ 8,200,000
Fees and expenses						$ 4,000,000
Secured Debt | US Treasury Rate | Loan Agreement
Debt Instrument [Line Items]
Margin for term loan						0.50%
Secured Debt | Repayment of Interests | Loan Agreement
Debt Instrument [Line Items]
Capacity available for specific purpose other than for trade purchases						$ 25,000,000
Secured Debt | Payments Related to Litigation | Loan Agreement
Debt Instrument [Line Items]
Capacity available for specific purpose other than for trade purchases						$ 50,000,000
Secured Debt | Scenario, Forecast | Loan Agreement
Debt Instrument [Line Items]
Additional borrowing capacity							$ 5,000,000
Minimum cash requirement		$ 10,000,000	$ 15,000,000	$ 20,000,000	$ 5,000,000

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Nov. 16, 2016
Affiliated Entity
Related Party Transaction [Line Items]
Free rent period	5 months
Monthly rental payments first five years	$ 60,000
Initial rent period	5 years
Monthly rental payments after five years	$ 63,000
Rent period after first five years	2 years
Member of Board of Directors
Related Party Transaction [Line Items]
Legal fees	$ 1,500,000	$ 602,000	$ 822,000
Accounts payable to related party	$ 93,573
Private Placement
Related Party Transaction [Line Items]
Share price				$ 2.49

Inventory - Schedule of Invento

Inventory - Schedule of Inventory (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Work in process	$ 18,916,084	$ 12,447,088
Finished goods	7,293,880	0
Inventory	$ 26,209,964	$ 12,447,088

Inventory - Narrative (Details)

Inventory - Narrative (Details)	12 Months Ended
	Dec. 31, 2015USD ($)
Inventory Disclosure [Abstract]
Inventory write-downs	$ 60,000

Property, Plant and Equipment -

Property, Plant and Equipment - Schedule of Property, Plant and Equipment (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Leasehold improvements, gross	$ 2,542,044	$ 2,542,044
Computer equipment, gross	770,479	754,502
Furniture and fixtures, gross	455,220	452,696
Property, plant and equipment, gross	3,767,743	3,749,242
Accumulated depreciation, depletion and amortization, property, plant, and equipment	(3,468,266)	(3,299,417)
Property, plant and equipment, net	$ 299,477	$ 449,825

Property, Plant and Equipment56

Property, Plant and Equipment - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Depreciation and other amortization	$ 174,275	$ 247,357	$ 351,561

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Payables and Accruals [Abstract]
Bonus	$ 2,357,194	$ 580,801
Professional fees	481,641	597,721
Vacation	262,664	227,863
Other (primarily R&D vendors and CMOs)	1,483,253	1,982,223
Accrued expenses and other current liabilities	$ 4,584,752	$ 3,388,608

Income Taxes Provision (Benefit

Income Taxes Provision (Benefit) for Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]
Current federal tax expense (benefit)	$ (5,093)	$ 439,934	$ (10,428)
Current state and local tax expense (benefit)	(1,446)	946	(30,375)
Current income tax expense (benefit)	(6,539)	440,880	(40,803)
Deferred federal income tax expense (benefit)	21,252	19,006	53,198,632
Deferred state and local income tax expense (Benefit)	(829)	2,097	370,439
Deferred income tax expense (benefit)	20,423	21,103	53,569,071
Benefit from (provision for) income taxes	$ 13,884	$ 461,983	$ 53,528,268

Income Taxes Deferred Tax Asset

Income Taxes Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Deferred income tax assets:
Net operating losses	$ 72,726,440	$ 22,701,028
Deferred research and development costs	669,602	1,130,413
Amortization of intangible assets	665,531	887,906
Share-based compensation	1,687,243	1,947,019
Fixed assets	667,008	662,011
Deferred revenue	102,520,433	59,892,477
Alternative minimum tax credits	2,029,190	2,034,283
Loss contingency	0	73,421,980
Other	1,337,941	0
Deferred income tax assets	182,303,388	162,677,117
Deferred income tax assets, net of valuation allowance	155,465,173	143,522,669
Deferred income tax assets, net of valuation allowance	26,838,215	19,154,448
Deferred income tax liabilities:
Amortization of goodwill	(287,729)	(267,598)
Capitalized contract costs	(25,854,435)	(18,922,571)
Other	(982,117)	(229,922)
Deferred income tax liability, net	$ 286,066	$ 265,643

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Valuation allowance, increase amount	$ 11,900,000
Federal net operating loss carryforwards	204,900,000
Deferred tax assets, alternative minimum tax	2,029,190	$ 2,034,283
Operating loss carryforwards from excess tax deduction on stock option activity	1,600,000
Unrecognized tax benefits	$ 0	$ 0

Income Taxes Effective Tax Rate

Income Taxes Effective Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Effective Income Tax Rate, Continuing Operations, Tax Rate Reconciliation [Abstract]
Statutory federal income tax rate	(35.00%)	(35.00%)	(35.00%)
State tax benefit	0.60%	(0.00%)	0.20%
Gain (loss) from fair value of common warrants	0.80%	(0.00%)	(0.00%)
Reorganization costs	3.30%	7.00%	0.40%
Other	0.20%	1.40%	(0.00%)
Valuation allowance on deferred tax assets	30.10%	27.80%	59.70%
Effective tax rate	(0.00%)	1.20%	25.30%

Commitments and Contingencies (

Commitments and Contingencies (Details)	May 13, 2011course	Apr. 30, 2015USD ($)	Dec. 31, 2016USD ($)course	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Nov. 16, 2016USD ($)	Dec. 23, 2015USD ($)	Jan. 15, 2015USD ($)
Loss Contingencies [Line Items]
Rent reduction		$ 35,000
Rent expense			$ 1,200,000	$ 1,400,000	$ 1,600,000
License Agreement litigation | Settled Litigation
Loss Contingencies [Line Items]
Final order and judgment								$ 195,000,000
Final order and judgment post-judgment interest							$ 30,663.89
Final order and judgment including interest						$ 217,000,000
BARDA Contract
Loss Contingencies [Line Items]
Number of courses to be delivered | course	2,000,000		2,000,000

Commitments and Contingencies63

Commitments and Contingencies Operating Leases (Details)	Dec. 31, 2016USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,017	$ 1,242,797
2,018	739,772
2,019	766,476
2,020	512,788
Total	$ 3,261,833

Financial Information By Quar64

Financial Information By Quarter (Unaudited) (Details) - USD ($)	3 Months Ended								12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Quarterly Financial Information [Abstract]
Research and development	$ 7,000	$ 5,000	$ 2,000	$ 1,000	$ 4,189,000	$ 1,327,000	$ 1,468,000	$ 1,192,000	$ 14,987,628	$ 8,175,878	$ 3,139,835
Selling, general and administrative expense	4,000	3,000	4,000	3,000	2,568,000	2,321,000	2,605,000	3,088,000	13,713,635	10,582,068	12,646,653
Research and development expense	8,000	6,000	3,000	3,000	4,934,000	2,427,000	2,959,000	2,811,000	19,710,673	13,130,529	10,707,354
Patent preparation fees	0	0	0	0	246,000	194,000	236,000	333,000	909,376	1,009,053	987,777
Interest on PharmAthene liability	1,000	4,000	4,000	3,000					11,668,900	0	0
Litigation accrual expense					14,393,000	14,000	0	0	0	14,407,494	188,465,065
Operating loss	(7,000)	(8,000)	(9,000)	(7,000)	(17,952,000)	(3,629,000)	(4,332,000)	(5,040,000)	(31,014,956)	(30,953,266)	(209,667,014)
Net income (loss)	$ (10,000)	$ (9,000)	$ (10,000)	$ (10,000)	$ (20,094,000)	$ (5,631,000)	$ (6,573,000)	$ (7,153,000)	$ (39,697,960)	$ (39,451,324)	$ (265,463,138)
Earnings (loss) per share: basic and diluted (usd per share)	$ (0.15)	$ (0.17)	$ (0.18)	$ (0.19)	$ (0.38)	$ (0.10)	$ (0.12)	$ (0.13)	$ (0.69)	$ (0.73)	$ (4.97)